August 17, 2021 George Sgouros, Ph.D. [Date of This Version]

______August 17, 2021 George Sgouros, Ph.D. [Date of this version]

CURRICULUM VITAE

Table of Contents Current Primary Appointment ...... 2 Current Secondary Appointments ...... 2 Biographical ...... 2 Education ...... 2 Postdoctoral Training ...... 3 Positions and Appointments ...... 3 Publications ...... 4 A. Peer-reviewed original research articles ...... 4 B. Books and Other Monographs ...... 19 Books ...... 19 Chapters/Review Articles ...... 19 C. Other ...... 23 Conference Proceedings ...... 23 Editorial/Commentary ...... 24 Media/interviews ...... 25 Patents and Software Copyrights ...... 26 Research Support (PI or Co-PI) ...... 26 Active ...... 26 Pending ...... 28 Previous ...... 28 Clinical Trials ...... 32 Teaching ...... 34 Mentoring ...... 35 Ph.D. Thesis committees ...... 39 Editorial Activities ...... 40 Scientific and Medical Societies ...... 40 Committees/Review Panels ...... 40 Honors & Awards ...... 42 Invited Talks, Panels ...... 42

GS 8/27/2021 1 sgourosCV_2021_08-27

______August 17, 2020 George Sgouros, Ph.D. [Date of this version]

CURRICULUM VITAE

Current Primary Appointment Johns Hopkins University, Professor of Radiology and Radiological Science, School of Medicine, Director, Radiological Physics Division, Baltimore MD 21205 Russel H Morgan Dept. of Radiology 2018- Current Secondary Appointments Johns Hopkins University Professor of Radiation Oncology, School of Medicine Baltimore MD 21205 2008-

Johns Hopkins University Professor of Oncology, School of Medicine Baltimore MD 21205 2009-

Biographical

Name George Sgouros Date of birth March 31, 1963 Place of birth Munich, Germany Citizenship United States Office Address 4M61 CRB II Tel. #: 410 614 0116 1550 Orleans St E-mail: [email protected] Johns Hopkins University, SOM Fax #: 413 487-3753 Baltimore MD 21231 Foreign Languages: Spoken – Greek, English

Education

Columbia University B.S. (Applied Physics) School of Engineering & Applied Science 1980-1984 New York, New York

Cornell University Ph.D. Graduate School of Medical Sciences, (Physiology & Biophysics) New York, New York 1986-1991

GS 8/27/2021 2 sgourosCV_2021_08-27

Postdoctoral Training

Sloan-Kettering Institute Post-doctoral Research Fellow Memorial Sloan-Kettering Cancer Center (Medical Physics) New York, New York 1991-1993

Positions and Appointments

Memorial Sloan-Kettering Cancer Center Assistant/Associate Member (Medical Physics) Memorial Hospital Assist./Assoc. Attending Physicist New York, NY 10021 1993-1998/1998-2003

Cornell University Medical College Assistant/Associate Professor in Radiology Cornell University (Radiology) New York, NY 10021 1994-1999/1999-2003

Johns Hopkins University, Visiting Associate Professor (Radiology), School of Medicine, Director, Radiopharm. Dosimetry Section, Baltimore MD 21205 Division of Nuclear Medicine, Dept. of Radiology 2003-2005

Johns Hopkins University, Associate Professor (Radiology), School of Medicine, Director, Radiopharm. Dosimetry Section, Baltimore MD 21205 Division of Nuclear Medicine, Dept. of Radiology 2005-2007

Johns Hopkins University, Professor (Radiology), School of Medicine, Director, Radiopharm. Dosimetry Section, Baltimore MD 21205 Division of Nuclear Medicine, Dept. of Radiology 2007-2018

GS 8/27/2021 3 sgourosCV_2021_08-27

Publications

A. Peer-reviewed original research articles

1. Bigler RE, Sgouros G. Biological analysis and dosimetry for 15O-labeled O , CO , and CO 2 2 gases administered continuously by inhalation. J Nucl Med 1983; 24(5):431-437.

2. Bigler RE, Zanzonico PB, Schmall B, Conti PS, Dahl JR, Rothman L, Sgouros G, MacEwen EG. Evaluation of [1-11C]-alpha-aminoisobutyric acid for tumor detection and amino acid transport measurement: Spontaneous canine tumor studies. Eur J Nucl Med 1985; 10:48-55.

3. Sgouros G, Barest G, Thekkumthala J, Chui C, Mohan R, Bigler RE, Zanzonico PB. Treatment planning for internal radionuclide therapy: Three-dimensional dosimetry for non- uniformly distributed radionuclides. J Nucl Med 1990; 31(11):1884-1891.

4. Sgouros G. Plasmapheresis in radioimmunotherapy of micrometastases: A mathematical modeling and dosimetrical analysis. J Nucl Med 1992; 33:2167-2179.

5. Sgouros G, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. J Nucl Med 1993; 34:422-430.

6. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 1993; 34:689-694.

7. Sgouros G, Chiu S, Pentlow KS, Brewster LJ, Kalaigian H, Baldwin B, Daghighian F, Graham MC, Larson SM, Mohan R. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 1993; 34:1595-1601.

8. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ, Larson SM, Scheinberg DA. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity. Blood 1994; 83(7):1760-1768.

9. Lief EP, Sgouros G, Humm JL. General solution of the radioactive parent-daughter relationship. Med Phys 1994; 21:1739-1740.

10. Scott AM, Macapinlac H, Zhang J, Kalaigian H, Graham MC, Divgi CR, Sgouros G, Goldsmith SJ, Larson SM. Clinical applications of fusion imaging in oncology. Nucl Med Biol 1994; 21:775-784.

11. Larson SM, Divgi CR, Scott A, Sgouros G, Graham MC, Kostakoglu L, Scheinberg D, Cheung NV, Schlom J, Finn RD. Current status of radioimmunotherapy. Nucl Med Biol 1994; 21(5):785-792.

12. Scott AM, Macapinlac H, Divgi CR, Zhang J, Kalaigian H, Welt S, Pentlow K, Hilton S, Graham MC, Sgouros G, Pelizzari C, Chen G, Schlom J, Goldsmith SJ, Larson SM. Clinical

GS 8/27/2021 4 sgourosCV_2021_08-27

validation of SPECT and CT/MRI registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. J Nucl Med 1994; 35:1976-1984.

13. Scott AM, Macapinlac H, Zhang J, Daghighian F, Montamayor N, Kalaigian H, Sgouros G, Graham MC, Yeh SDJ, Lai E, Goldsmith SJ, Larson SM. Image registration of SPECT and CT images using an external fiduciary band and 3-D surface fitting in a case of metastatic thyroid cancer. J Nucl Med 1995; 36:100-103.

14. Willins J, Sgouros G. Modeling analysis of Platinum-195m for targeting individual blood- borne cells in adjuvant radioimmunotherapy. J Nucl Med 1995; 36:315-319.

15. Ugur O, Scott AM, Kostakoglu L, Hui TE, Masterson ME, Febo R, Sgouros G, Rosa E, Mehta B, Fisher DR, Cheung NV, Larson SM. Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model. Nucl Med Biol 1995; 22(1):87-93.

16. Nikula TK, Bocchia M, Curcio MJ, Sgouros G, Ma Y, Finn RD, Scheinberg DA. Impact of the high tyrosine fraction in complementarity determining regions: Measured and predicted effects of radioiodination on IgG immunoreactivity. Molecular Immunol 1995; 32:865-872.

17. Sgouros G, Jureidini IM, Scott AM, Graham MC, Larson SM, Scheinberg DA. Bone marrow dosimetry: Regional variability of marrow-localizing antibody. J Nucl Med 1996; 37:695-698.

18. Furhang EE, Sgouros G, Chui C-S. Radionuclide photon dose kernels for internal emitter dosimetry. Med Phys 1996; 23:759-764.

19. Furhang EE, Chui C-S, Sgouros G. A Monte Carlo approach to patient-specific dosimetry. Med Phys 1996, 23:1523-1529.

20. Kolbert KS, Sgouros G, Scott AM, Bronstein JE, Malane RA, Zhang J, Kalaigian H, McNamara S, Schwartz L, Larson SM. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med 1997; 38:301-308.

21. Furhang EE, Chui C-S, Kolbert KS, Larson SM, Sgouros G. Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys 1997, 24:1163-1172.

22. Loh A, Sgouros G, O'Donoghue JA, Deland D, Puri D, Capitelli P, Humm JL, Larson SM, Old LJ, Divgi CR. A pharmacokinetic model of 131I-G250 antibody in patients with renal cell carcinoma. J Nucl Med 1998; 39:484-489.

23. Slovin SF, Scher HI, Divgi CR, Reuter V, Sgouros G, Moore M, Weingard K, Pettengall R, Imbriaco M, El-Shirbiny A, Finn R, Bronstein J, Brett C, Milenic D, Dnistrian A, Shapiro L, Schlom J, and Larson SM. Interferon- and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 1998; 4:643- 651.

GS 8/27/2021 5 sgourosCV_2021_08-27

24. Behr TM, Sgouros G, Vougiokas V, Memtsoudis S, Gratz S, Schmidberger H, Blumenthal RD, Goldenberg DM, Becker W. Therapeutic efficacy and dose-limiting toxicity of Auger- electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer 1998;76:738-748.

25. Sgouros G. Yttrium-90 biodistribution by yttrium-87 imaging: A feasibility analysis. Med. Phys. 1998; 25:1487-1490.

26. Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI. Positron emission tomography of a human prostate cancer xenograft: Association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res, 1998; 58:3009-3014.

27. Sgouros G, O'Donoghue JA, Larson SM, Macapinlac H, Larson JJ, Kemeny N. Mathematical model of 5-[125I]iodo-2'-deoxyuridine treatment: Continuous infusion regimens for hepatic metastases. Int J Radiat Biol Oncol Phys 1998; 41:1177-1183.

28. Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ. Phase I/II radioimmunotherapy trial with iodine-131 labeled monoclonal antibody (Mab) G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4:2729-2739.

29. McDevitt MR, Finn RD, Sgouros G, Ma D, Scheinberg DA. An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation. Appl. Radiat. Isotopes 1999; 50:895-904.

30. Griffiths GL, Govindan SV, Sgouros G, Ong GL, Goldenberg DM, Mattes MJ. Cytotxicity with Auger electron-emitting radionuclides delivered by antibodies. Int J Cancer 1999; 81:985-992.

31. Sgouros G, Ballangrud ÅM, Humm JL, Jurcic JG, McDevitt MR, Erdi YE, Mehta BM, Finn RD, Geerlings MW, Larson SM, Scheinberg DA. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med, 1999; 40:1935-1946.

32. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 1999; 40:2102-2106.

33. Ballangrud ÅM, Yang W-H, Dnistrian A, Lampen NM, Sgouros G. Growth and characterization of LNCaP prostate cancer cell spheroids. Clin Cancer Res 1999; 5:3171s- 3176s.

34. Behr TM, Sgouros G, Stabin MG, Behe M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha- emitters. Clin Cancer Res. 1999 Oct;5(10 Suppl):3031s-3043s.

GS 8/27/2021 6 sgourosCV_2021_08-27

35. Hamacher KH, Sgouros G. A schema for estimating absorbed dose to organs following the administration of radionuclides with multiple unstable daughters: A matrix approach. Med Phys 1999; 26:2526-2528

36. O’Donoghue JA, Sgouros G, Divgi CR, Humm JL. Single dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry. J Nucl Med 2000; 41:538-547.

37. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ. Prognostic value of FDG-PET scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85:1107-1113.

38. Sgouros G, Stabin M, Erdi Y, Akabani G, Kwok C, Brill AB, Wessels B. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone or blood components. Med Phys 2000; 27:2150-2164.

39. Behr TM, Behe M, Lohr M, Sgouros G, Angerstein C, Wehrmann E, Nebendahl K, Becker W. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nuc Med 2000; 27:753-765.

40. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang W, Finn RD, Pellegrini V, Geerlings MW, Jr., Lee M, Brechbiel MW, Bander NH, Cordon- Cardo C, Scheinberg DA. An alpha-particle emitting antibody (J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000; 60:6095-6100.

41. Govindan SV, Goldenberg DM, Elsamra SE, Griffiths GL, Ong GL, Brechbiel MW, Burton J, Sgouros G, Mattes MJ. Radionuclides linked to CD74 antibody as therapeutic agents for B- cell lymphoma: Comparison of Auger electron emitters with -particle emitters. J Nucl Med 2000; 41:2089-2097.

42. Kolbert KS, Hamacher KA, Jurcic JG, Scheinberg DA, Larson SM, Sgouros G. Parametric images of antibody pharmacokinetics in Bi-213-HuM195 Therapy of Leukemia. J Nucl Med 2001; 42:27-32.

43. Hamacher KA, Den RB, Den EI, Sgouros G. Cellular dose conversion factors for alpha- particle emitting radionuclides of interest in radionuclide therapy. J Nucl Med 2001; 42:1216- 1221.

44. Emfietzoglou D, Kostarelos K, Sgouros G. An analytical dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med 2001; 42:499-504.

45. Barendswaard EC, Welt S, Humm JL, O'Donoghue JA, Sgouros G, Finn RD, Scott AM, Larson SM, Old LJ. Relative therapeutic efficacy of I-125 and I-131 labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med 2001; 42:1251-1256.

46. Ballangrud AM, Yang W, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, Bander NH, Scheinberg DA, Sgouros G. Response of LNCaP spheroids following treatment

GS 8/27/2021 7 sgourosCV_2021_08-27

with alpha-particle emitter (213Bi)-labeled anti-PSMA antibody (J591). Cancer Res 2001; 61:2008-2014.

47. Thomas SR, Watson EE, Bolch WE, Brill AB, Charkes ND, Fisher DR, Hays MT, Howell RW, Meredith RF, Robertson JS, Sgouros G, Siegel JA, Wessels BW. MIRD Pamphlet No. 18: Administered cumulated activity for ventilation studies. J Nucl Med 2001; 42:520-526.

48. Hamacher KA, Sgouros G. Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters. Med Phys 2001; 28:1857-1874.

49. DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm JL, DeNardo SJ. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 2002; 94(4 Suppl):1332-48.

50. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud ÅM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted  particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233-1239.

51. O'Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. Hematologic toxicity in radioimmunotherapy: Dose-response relationships in I-131 labeled antibody therapy. Cancer Biother Radiopharm 2002; 17:435-443.

52. Behr RM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm 2002; 17:445-464.

53. Sgouros G, Squeri S, Ballangrud ÅM, Kolbert KS, Teitcher JB, Panageas KS, Finn RD, Divgi CR, Larson SM, Zelenetz AD. Patient-Specific, 3-D dosimetry in Non-Hodgkin’s Lymphoma Patients Treated with 131I-anti-B1 Antibody: Assessment of tumor dose-response. J Nucl Med 2003; 44:260-268.

54. Kolbert KS, Watson T, Matei C, Xu S, Koutcher JA, Sgouros G. Murine S-factors for Liver, Spleen and Kidney. J Nucl Med 2003; 44 784-791

55. Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA, Clairand I, Sgouros G. MIRD pamphlet no. 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med. 2003; 44:1113-1147

56. Palm S, Enmon RM, Matei C, Kolbert KS, Xu S, Pellegrini V, Zanzonico PB, Finn RL, Koutcher JA, Larson SM, Sgouros G. Pharmacokinetics and biodistribution of 86Y- Trastuzumab for 90Y dosimetry in an ovarian carcinoma model: Correlative microPET and MRI. J Nucl Med 2003; 44:1148-1155.

57. Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG. Cytoreduction with iodine-131-anti-

GS 8/27/2021 8 sgourosCV_2021_08-27

CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant 2003; 32:549-56.

58. Enmon R, Yang W, Ballangrud ÅM, Solit DB, Heller G, Rosen N, Scher HI, Sgouros G. Combination treatment with 17AAG and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res 2003; 63: 8393-8399.

59. Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. Pharmacokinetics and toxicity of the targetable atomic generator, actinium-225-HuM195 in non-human primates. J Nucl Med 2004; 45:129-37.

60. Sofou S, Thomas JL, Lin H, McDevitt MR, Scheinberg DA, Sgouros G. Engineered liposomes for potential -particle therapy of metastatic cancer. J Nucl Med 2004; 45:253-260.

61. Ballangrud ÅM, Yang W-H, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G. Alpha-particle emitting atomic generator (225Ac)-labeled Trastuzumab (Herceptin) targeting of breast cancer spheroids: Efficacy versus HER2/neu expression. Clin Cancer Res, 2004; 10:4489-97.

62. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ, Larson SM. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I-PET and 3D-ID. J Nucl Med, 2004; 45:1366-72.

63. Kostarelos K, Emfietzoglou D, Papakostas A, Yang W-H, Ballangrud ÅM, Sgouros G. Binding and interstitital penetration of liposomes with avascular tumor spheroids. Int J Cancer, 2004 Nov 20;112(4):713.

64. Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, Stabin MG, Sgouros G. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med 2004; 45:1725-33.

65. Emfietzoglou D, Kostarelos K, Papakostas A, Yang W-H, Ballangrud ÅM, Song H, Sgouros G. Liposome mediated radiotherapeutics using avascular tumor spheroids: Comparative dosimetry study for various radionuclides, liposome systems and a targeting antibody. J Nucl Med 2005; 46:89-97.

66. Watchman CJ, Jokisch DW, Patton PW, Rajon DA, Sgouros G, Bolch WE. Absorbed fractions for alpha particles in tissues of trabecular bone-considerations of marrow cellularity within the ICRP reference male. J Nucl Med 2005; 47:1171-1185.

67. Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA. Efforts to control the errant products of a targeted in vivo generator. Cancer Res; 2005; 65:4888-4895.

68. Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA. Renal tubulo- interstitial changes following internal irradiation with alpha-particle emitting actinium daughters. J Amer Soc Nephrology 2005; 16(9):2677-89.

GS 8/27/2021 9 sgourosCV_2021_08-27

69. Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud AM, Sgouros G. Enginering lipid vesicles of enhanced intratumoral transport capabilities: Correlating liposome characteristics with penetration into human prostate tumor spheroids. J Liposome Res 2005; 15:15-27.

70. Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E, Scheinberg DA. Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Physics 2006; 64:1503-12.

71. Sgouros G, Song H, Ladenson PW, Wahl RL. Lung toxicity in radioiodine therapy of thyroid carcinoma: Development of a dose-rate method and dosimetric Implications of the 80 mCi rule. J Nucl Med, 2006; 47:1977-1984 (PMC2974326).

72. Song H, He B, Prideaux AR, Du Y, Frey EC, Kasecamp W, Ladenson PW, Wahl RL, Sgouros G. Lung dosimetry for radioiodine therapy treatment planning in the case of diffuse lung metastases. J Nucl Med, 2006; 47:1985-1994.

73. Song H, Du Y, Sgouros G, Prideaux AR, Frey EC, Wahl RL. Therapeutic potential of 90Yttrium and 131Iodine-labeled anti-CD20 monoclonal antibody in treating Non-Hodgkin’s lymphoma patients with pulmonary involvement: A Monte Carlo based dosimetric analysis. J Nucl Med, 2007; 48:150-157.

74. Prideaux AR, Song H, Hobbs RF, He B, Frey EC, Ladenson PW, Wahl RL, Sgouros G. Three- Dimensional Radiobiological Dosimetry (3D-RD): Application of radiobiological modeling to patient-specific, 3-D imaging-based internal dosimetry. J Nucl Med, 2007; 48:1008-1016.

75. Petoussi-Henss N, Bolch WE, Zankl M, Sgouros G, Wessels B. Patient-specific scaling of reference s-values for cross-organ radionuclide s-values: what is appropriate? Radiat Prot Dosimetry. 2007;127(1-4):192-6

76. Singh Jaggi J, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, Schwartz J, Beattie B, Kappel BJ, Chattopadhyay D, Xiao J, Sgouros G, Larson SM, Scheinberg DA. Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. J Clin Invest. 2007 Sep 4;117(9):2422-2430.

77. Sofou S, Kappel BJ, Jaggi JS, McDevitt MR, Scheinberg DA, Sgouros G. Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers. Bioconjug Chem 2007 Nov-Dec; 18(6):2061-7 (PMC2582153).

78. Sgouros G, Hong S. Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis. Cancer Biother Radipahrm. 2008 23:74-81 (PMC2977973).

79. Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys. 2008 35:1123-1134 (PMC2974633).

80. Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ, Sgouros G, Kozikowski AP, Pomper MG. N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-

GS 8/27/2021 10 sgourosCV_2021_08-27

[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14(10):3036-43 (PMC3078104).

81. Zhao JM, Har-el Y, McMahon MT, Zhou J, Sherrry DA, Sgouros G, Bulte JWM, van Zijl PCM. Size-induced enhancement of chemical exchange saturation transfer (CEST) contrast in liposomes. J Am Chem Soc. 130 (15), 5178–5184, 2008 (PMC2759111).

82. Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, Huang LQ, Murata S, Sgouros G, Emens LA, Reilly RT, Jaffee EM. Antibody enhanced HER-2/neu targeted vaccine induction of CD8+ T cell responses through the Fc-activation of dendritic cells. J Clin Invest. 2008; 118(5):1700-11 (PMC2289797).

83. Song H, Shahverdi K, Huso DL, Esaias C, Fox J, Liedy A, Zhang Z, Reilly RT, Apostolidis C, Morgenstern A, Sgouros G. 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgnic mouse model. Cancer Res. 2008; 68(10):3873-80 (PMC2981030).

84. He B, Wahl RL, Du Y, Sgouros G, Jacene H, Flinn I and Frey EC. Comparison of Residence Time Estimation Methods for Radioimmunotherapy Dosimetry and Treatment Planning - Monte Carlo Simulation Studies. IEEE Trans. Med. Img. 2008; 27(4): 521-530 (PMC2588667).

85. Song H, Shahverdi K, Huso DL, Wang Y, Fox J, Hobbs RF, Gimi B, Gabrielson K, Pomper MG, Tsui B, Bhujwalla Z, Reilly RT, Sgouros G. An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer. Clin Cancer Res. 2008; 14(19):6116-25 (PMC2570093).

86. Fu D, Tanhehco Y, Chen J, Foss CA, Fox JJ, Chong J, Hobbs RF, Fukayama M, Sgouros G, Kowalski J, Pomper MG, Ambinder RF. Bortezomib-induced enzyme-targeted radiotherapy in herpes virus-associated tumors. Nat Med 2008;14(10):1118-22 (PMC2709824).

87. Baechler S, Hobbs RF, Prideaux AR, Recordon M, Bischof-Delaloye A, Sgouros G. Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan. Cancer Biother Radiopharm 2008; 23(5):633-9 (PMC2936951).

88. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, Green AJ, Bouchet LG, Brill AB, Bolch WE, Sgouros G, Thomas SR. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy. J Nucl Med 2008; 49(11):1884-99

89. He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H, Frey EC. Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys 2009; 36(2):612-619 (PMC2848525).

90. Hobbs RF, Sgouros G. Calculation of the biological effective dose for piecewise defined dose- rate fits. Med Phys. 2009 Mar;36(3):904-7 (PMC2736747).

GS 8/27/2021 11 sgourosCV_2021_08-27

91. Loeb DM, Garrett-Mayer E, Hobbs RF, Prideaux AR, Sgouros G, Shokek O, Wharam MD Jr, Scott T, Schwartz CL. Dose-finding study of (153)Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009 115(11):2514-22 (PMC2974628).

92. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry--Standardization of Nomenclature. J Nucl Med 2009; 50(3):477-484 .

93. He B, Wahl RL, Sgouros G, Du Y, Jacene H, Kasecamp WR, Flinn I, Hammes RJ, Bianco J, Kahl B, Frey EC. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning – patient studies. Med Phys 2009; 36:1595-1601 (PMC2851232).

94. Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, Chien DT, Ewertz ME, Esaias CE, Ladenson PW, Sgouros G. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: Real-time treatment planning and methodological comparison. J Nucl Med, 2009; 50(11):1844-1847 (PMC2844448).

95. Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, Morgenstern A, Sgouros G. Radioimmunotherapy of breast cancer metastases with alpha-particle-emitter 225Ac: Comparing efficacy with 213Bi, 90Y. Cancer Res, 2009;69(23):8941-8 (PMC2789180).

96. Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A. Pre-therapeutic 124I PET/CT dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010 May;37(5):884-95 (PMC2854857).

97. Sofou S, Enmon R, Palm S, Kappel B, Zanzonico P, McDevitt MR, Scheinberg DA, Sgouros G. Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. J Liposome Res. 2010 Dec;20(4):330-40 (PMC3172685).

98. Hobbs RF, Baechler S, Senthamizhchelvan S, Prideaux AR, Esaias CE, Reinhardt M, Frey EC, Loeb DM, Sgouros G. Camera saturation in whole body planar imaging: An algorithmic solution. Phys Med Biol. 2010 Feb 7;55(3):817-31 (PMC2844671).

99. Hobbs RF, Baechler S, Wahl RL, He B, Song H, Esaias CE, Frey EC, Jacene H, Sgouros G. Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. J Nucl Med, 2010 Mar;51(3):368-75 (PMC2967028).

100. Lingappa, M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, Sgouros G. Immunoliposomal Delivery of 213Bi for α-Emitter Targeting of Metastatic Breast Cancer. Cancer Res 2010 Sep 1;70(17):6815-23 (PMC2977986).

101. Loeb DM, Hobbs RF, Okoli A, Chen AR, Cho S, Srinivasan S, Sgouros G, Shokek O, Wharam MD Jr, Scott T, Schwartz CL. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer. 2010 Dec 1;116(23):5470-8 (PMC2991401).

GS 8/27/2021 12 sgourosCV_2021_08-27

102. Dieudonné A, Hobbs RF, Bolch WE, Sgouros G, Gardin I. Fine-Resolution Voxel S Values for Constructing Absorbed Dose Distributions at Variable Voxel Size. J Nucl Med. 2010 Oct;51(10):1600-7 (PMC2974318).

103. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential Cytarabine and {alpha}-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia. Clin Cancer Res. 2010 Nov 1;16(21):5303-11 (PMC2970691).

104. Baechler S, Hobbs RF, Jacene HA, Bochud FO, Wahl RL, Sgouros G. Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131I- Tositumomab. J Nucl Med, 2010 Dec;51(12):1878-84 (PMC3169802).

105. Hobbs RF, McNutt T, Baechler S, He B, Esaias CE, Frey EC, Loeb DM, Wahl RL, Shokek O, Sgouros G. A treatment planning method for sequentially combining radiopharmaceutical therapy (RPT) with external radiation therapy (XRT). Int J Radiat Oncol Biol Phys, 2011 80:1256-62 (PMC3090537)

106. Senthamizhchelvan S, Bravo PE, Esaias C, Lodge MA, Merrill J, Hobbs RF, Sgouros G, Bengel FM Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med. 2011 Oct;51(10):1592-9 (PMC3172678).

107. Senthamizhchelvan S, Bravo PE, Esaias C, Lodge MA, Merrill J, Hobbs RF, Bengel FM, 82 Sgouros G. Radiation dosimetry of Rb in humans under pharmacologic stress. J Nucl Med. 2011 Mar;52(3):485-91 (PMC3172687)

108. Hobbs RF, Baechler S, Fu DX, Esaias C, Pomper MG, Ambinder RF, Sgouros G. A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy. Med Phys 2011 Jun;38(6):2892-903 (PMC3117894).

109. Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)- Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer. Clin Cancer Res 2011;17 7645-7653 (PMC3243762).

110. Sgouros G, Frey EC, Bolch WE, Wayson MB, Abadia AF, Treves ST. An approach for balancing diagnostic image quality with cancer risk: application to pediatric diagnostic imaging of 99mTc-dimercaptosuccinic acid. J Nucl Med. 2011; 52(12):1923-9 (PMC3290866).

111. Senthamizhchelvan S, Hobbs RF, Song H, Frey EC, Zhang Z, Armour E, Wahl RL, Loeb DM, Sgouros G. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. J Nucl Med. 2012;53:215-24 (PMC3291096).

112. Wayson M, Lee C, Sgouros G, Treves ST, Frey E, Bolch WE. Internal photon and electron dosimetry of the newborn patient--a hybrid computational phantom study. Phys Med Biol. 2012; 57:1433-57 (PMC pending).

GS 8/27/2021 13 sgourosCV_2021_08-27

113. Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS One. 2012;7:e31962 (PMC3281086).

114. Liu G, Moake M, Har-El YE, Long CM, Chan KW, Cardona A, Jamil M, Walczak P, Gilad AA, Sgouros G, van Zijl PC, Bulte JW, McMahon MT. In vivo multicolor molecular MR imaging using diamagnetic chemical exchange saturation transfer liposomes. Magn Reson Med. 2012 67:1106–1113 (PMC3522097).

115. Cheng Y, Senthamizhchelvan S, Agarwal R, Green GM, Mease RC, Sgouros G, Huso DL, Pomper MG, Meltzer SJ, Abraham JM. [( 32) P]ATP inhibits the growth of xenografted tumors in nude mice. Cell Cycle 2012 11:1878-1882 (PMC3359117).

116. Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, Flux GD, Sgouros G. A bone marrow toxicity model for (223)Ra alpha-emitter radiopharmaceutical therapy. Phys Med Biol. 2012 57:3207-22 (PMC3442928).

117. Hobbs RF, Song H, Huso DL, Sundel M, Sgouros G. A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry. Phys Med Biol. 2012; 57:4403-24 (PMC3465844).

118. Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, Zanzonico PB, Ljungberg M. MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy. J Nucl Med. 2012; 53:1–16 (PMC3465844).

119. Baechler S, Hobbs RF, Boubaker A, Buchegger F, He B, Frey EC, Sgouros G. Three- dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy. Med Phys. 2012; 39:6118-6128 (PMC3465355).

120. Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, Kozikowski AP, Pomper MG. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.J Nucl Med. 2012 Dec;53(12):1883-91 (PMC3742115)

121. Dieudonné A, Hobbs RF, Lebtahi R, Maurel F, Baechler S, Wahl RL, Boubaker A, Le Guludec D, Sgouros G, Gardin I. Study of the Impact of Tissue Density Heterogeneities on 3- Dimensinal Abdominal Dosimetry: Comparison Between Dose Kernel Convolution and Direct Monte Carlo Methods. J Nucl Med. 2013 Feb;54(2):236-43 (PMC4060982)

122. Hobbs RF, Jentzen W, Bockisch A, Sgouros G. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET. Q J Nucl Med Mol Imaging. 2013 Mar;57(1):79-91 (PMC4037814)

123. Cheng L, Hobbs RF, Segars PW, Sgouros G, Frey EC. Improved dose-volume histogram estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction parameters. Phys Med Biol. 2013 Jun 7;58(11):3631-47. (PMC4151254)

GS 8/27/2021 14 sgourosCV_2021_08-27

124. Hobbs RF, Wahl RL, Frey EC, Kasamon Y, Song H, Huang P, Jones RJ, Sgouros G. Radiobiological optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin’s lymphoma. J Nucl Med 2013 54(9):1535-42. (PMC4142210)

125. Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, DeWeese TL, Sgouros G. Targeting Aberrant DNA double strand break repair in triple negative breast cancer with alpha particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther. 2013 Oct;12(10):2043-54. (PMC3804319)

126. Botta F, Mariani A, Hobbs RF, Vergara Gil A, Pacilio M, Parodi K, Cremonesi M, Coca Pérez MA, Di Dia A, Ferrari M, Guerriero F, Battistoni G, Pedroli G, Paganelli G, Torres Aroche LA, Sgouros G. Use of the FLUKA monte carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images. Phys Med Biol 2013 58(22):8099-120. (PMC4037810)

127. Hobbs RF, Howell RW, Song H, Baechler S, Sgouros G. Redefining relative biological effectiveness in the context of the EQDX formalism: Implications for alpha-particle emitter therapy. Rad Res 2014 Jan; 181(1):90-98. (PMC3984880)

128. Cheng L, Hobbs RF, Sgouros G, Frey EC. Development and evaluation of convergent and accelerated penalized SPECT image reconstruction methods for improved dose-volume histogram estimation in radiopharmaceutical therapy. Med Phys 2014 Nov; 41(11):2507 (PMC4241887)

129. Banerjee SR, Foss CA, Pullambhatla M, Wang Y, Srinivasan S, Hobbs RF, Baidoo KE, Brechbiel MW, Nimmagadda S, Mease RC, Sgouros G, Pomper MG. Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates. J Nucl Med. 2015 Apr;56(4):628-34

130. Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, Pomper MG. Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)- Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015 Apr 21. [Epub ahead of print]

131. Kiess AP, Minn I, Chen Y, Hobbs R, Sgouros G, Mease RC, Pullambhatla M, Shen CJ, Foss CA, Pomper MG. Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen. J Nucl Med. 2015 Sep;56(9):1401-7. doi: 10.2967/jnumed.115.155929. Epub 2015 Jul 16.

132. Woliner-van der Weg W, Schoffelen R, Hobbs RF, Gotthardt M, Goldenberg DM, Sharkey RM, Slump CH, van der Graaf WT, Oyen WJ, Boerman OC, Sgouros G, Visser EP. Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. EJNMMI Phys. 2015 Dec;2(1):5. doi: 10.1186/s40658-014- 0104-x. Epub 2015 Feb 24.

133. Josefsson A, Nedrow JR, Park S, Banerjee SR, Rittenbach A, Jammes F, Tsui B, Sgouros G. Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an

GS 8/27/2021 15 sgourosCV_2021_08-27

Immunocompetent Mouse Model of Breast Cancer. Cancer Res. 2015 Nov 10. [Epub ahead of print]

134. Plyku D, Loeb DM, Prideaux AR, Baechler S, Wahl RL, Sgouros G, Hobbs RF. Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry. Cancer Biother Radiopharm. 2015 Nov;30(9):369-79. doi: 10.1089/cbr.2014.1803

135. O’Reilly SE, Plyku D, Sgouros G, Fahey FH, Treves TS, Frey EC, Bolch WE. A risk index for pediatric patients undergoing diagnostic imaging with (99m)Tc-dimercaptosuccinic acid that accounts for body habitus. Phys Med Biol. 2016 Mar 21;61(6):2319-32. PMID: 26930549

136. Khamwan K, Plyku D, O'Reilly SE, Goodkind A, Cao X, Fahey FH, Treves ST, Bolch WE, Sgouros G. Pharmacokinetic modeling of [(18)F]fluorodeoxyglucose (FDG) for premature infants, and newborns through 5-year-olds. EJNMMI Res. 2016 Dec;6(1):28. PMID: 26988861

137. Yoshida T, Jin K, Song H, Park S, Huso DL, Zhang Z, Liangfeng H, Zhu C, Bruchertseifer F, Morgenstern A, Sgouros G, Sukumar S.Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer. Oncotarget. 2016 Apr 23. PMCID: PMC5078096

138. Kiess A, Minn IL, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, Brummet M, Chen Y, Choi J, Koumarianou E, Baidoo K, Brechbiel M, Mease RC, Sgouros G, Zalutsky MR, Pomper M. (2S)-2-(3-(1-Carboxy-5-(4-[211At]astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy. J Nucl Med. 2016 Oct;57(10):1569-1575. PMID: 27230930

139. Chen Y, Lisok A, Chatterjee S, Wharram B, Pullambhatla M, Wang Y, Sgouros G, Mease RC, Pomper MG. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance. Bioconjug Chem. 2016 Jul 20;27(7):1655-62. PMID: 27270097

140. Geyer AM, Schwarz BC, Hobbs RF, Sgouros G, Bolch WE. Quantitative impact of changes in marrow cellularity, skeletal size, and bone mineral density on active marrow dosimetry based upon a reference model. Med Phys. 2017 Jan; 44(1):272-283. doi: 10.1002/mp.12002

141. Geyer AM, Schwarz BC, O'Reilly SE, Hobbs RF, Sgouros G, Bolch WE Depth-dependent concentrations of hematopoietic stem cells in the adult skeleton: Implications for active marrow dosimetry. Med Phys. 2017 Feb;44(2):747-761. doi: 10.1002/mp.12056. Epub 2017 Jan 30

142. Plyku D, Hobbs RF, Huang K, Atkins F, Garcia C, Sgouros G, Van Nostrand D. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT- Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer. J Nucl Med. 2017 Jul;58(7):1146-1154

143. Nedrow JR, Josefsson A, Park S, Ranka S, Roy S, Sgouros G. Imaging of programmed death ligand-1 (PD-L1): Impact of protein concentration on distribution of anti-PD-L1 SPECT agent

GS 8/27/2021 16 sgourosCV_2021_08-27

in an immunocompetent melanoma murine model. J Nucl Med jnumed.117.193268 published ahead of print May 18, 2017 (10.2967/jnumed.117.193268)

144. Park S, Nedrow JR, Josefsson A, Sgouros G. Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice: characterization and use in a model of metastatic breast cancer. Oncotarget. 2017 Jul 10;8(40):68071-68082. doi: 10.18632/oncotarget.19174. eCollection 2017 Sep 15

145. Nedrow JR, Josefsson A, Park S, Bäck T, Hobbs RF, Brayton C, Bruchertseifer F, Morgenstern A, Sgouros G. Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter- labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Res. 2017 Dec;7(1):57. doi: 10.1186/s13550-017-0303-2. Epub 2017 Jul 18

146. Josefsson A, Hobbs RF, Ranka S, Schwarz BC, Plyku D, Willegaignon J, Buchpiguel AC, Sapienza MT, Bolch WE, Sgouros G. Comparative Dosimetry for 68Ga-DOTATATE: Impact of using Updated ICRP phantoms, S values and Tissue Weighting Factors. J Nucl Med Epub 2018

147. Plyku D, Mena E, Rowe SP, Lodge MA, Cho SY, Pomper MG, Sgouros G, Hobbs RF. Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent. Eur J Nucl Med Mol Imaging (2018) Feb 19. doi: 10.1007/s00259-018-3939-x. [Epub ahead of print].

148. Foss CA, Plyku D, Ordonez AA, Sanchez-Bautista J, Rosenthal HB, Minn I, Lodge MA, Pomper MG, Sgouros G, Jain SK. Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation. J Nucl Med. 2018 Nov;59(11):1751-1756

149. Li Y, O'Reilly S, Plyku D, Treves ST, Du Y, Fahey F, Cao X, Jha AK, Sgouros G, Bolch WE, Frey EC. A projection image database to investigate factors affecting image quality in weight- based dosing: application to pediatric renal SPECT. Phys Med Biol. 2018 Jul 9;63(14):145004

150. Khamwan K, O'Reilly SE, Plyku D, Goodkind A, Josefsson A, Cao X, Fahey FH, Treves ST, Bolch WE, Sgouros G. Re-evaluation of pediatric 18F-FDG dosimetry: Cristy-Eckerman versus UF/NCI hybrid computational phantoms. Phys Med Biol. 2018 Aug 14;63(16):165012

151. Foss CA, Plyku D, Ordonez AA, Sanchez-Bautista J, Rosenthal HB, Minn I, Lodge MA, Pomper MG, Sgouros G, Jain SK. Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation. J Nucl Med. 2018 Nov;59(11):1751-1756.

152. Ray Banerjee S, Minn IL, Kumar V, Josefsson A, Lisok A, Brummet M, Chen J, Kiess A, Baidoo K, Brayton C, Mease RC, Brechbiel M, Sgouros G, Hobbs RF, Pomper MG. Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2019 Jun 28. pii: jnumed.119.229393. doi: 10.2967/jnumed.119.229393. [Epub ahead of print]

153. Coura-Filho GB, Hoff AAFO, Duarte PS, Buchpiguel CA, Josefsson A, Hobbs RF, Sgouros G, Sapienza MT. 68Ga-DOTATATE PET: temporal variation of maximum standardized uptake

GS 8/27/2021 17 sgourosCV_2021_08-27

value in normal tissues and neuroendocrine tumours. Nucl Med Commun. 2019 Sep;40(9):920- 926

154. Srinivasan S, Crandall J, Gajwani P, Sgouros G, Mena E, Lodge MA, Wahl RL. Human Radiation Dosimetry of Orally or Intravenously Administered 18F-Fluorodeoxyglucose. J Nucl Med. 2019 Oct 18. pii: jnumed.119.233288. doi: 10.2967/jnumed.119.233288. [Epub ahead of print]

155. Li Y, O'Reilly S, Plyku D, Treves ST, Fahey F, Du Y, Cao X, Sexton-Stallone B, Brown J, Sgouros G, Bolch WE, Frey EC. Current pediatric administered activity guidelines for 99m Tc-DMSA SPECT based on patient weight do not provide the same task-based image quality. Med Phys. 2019 Nov;46(11):4847-4856

156. Karimian A, Ji NT, Song H, Sgouros G. Mathematical Modeling of Pre-Clinical Alpha-Emitter Radiopharmaceutical Therapy. Cancer Res. 2020; 80 (4), 868-876

157. Josefsson A, Siritantikorn K, Ranka S, de Amorim de Carvalho JW, Buchpiguel CA, Sapienza MT, Bolch WE, Sgouros G. Accuracy in Dosimetry of Diagnostic Agents: Impact of the Number of Source Tissues Used in Whole Organ S Value-Based Calculations. EJNMMI Res 2020; Mar 19;10(1):26. doi: 10.1186/s13550-020-0614-6

158. Olguin E, President B, Ghaly M, Frey E, Sgouros G, Bolch WE. Specific absorbed fractions and radionuclide S-values for tumors of varying size and composition. Phys Med Biol 2020 Sep 29. doi: 10.1088/1361-6560/abbc7e. Online ahead of print.

159. Yu J, Lu R, Nedrow JR, Sgouros G. Response of breast cancer carcinoma spheroids to combination therapy with radiation and DNA-PK inhibitor: growth arrest without a change in α/ β ratio. Int J Radiat Biol. 2020 Dec;96(12):1534-1540.

160. Brown JL, Sexton-Stallone B, Li Y, Frey EC, Treves ST, Fahey FH, Plyku D, Cao X, Sgouros G, Bolch WE. Body morphometry appropriate computational phantoms for dose and risk optimization in pediatric renal imaging with Tc-99m DMSA and Tc-99m MAG3. Phys Med Biol. 2020 Nov 27;65(23):235026

161. Ray S, Lisok A, Minn IL, Josefsson A, Kumar V, Brummet M, Boinapally S, Brayton C, Mease RC, Sgouros G, Hobbs RF, Pomper MG. Preclinical evaluation of 213 Bi-/ 225 Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2020 Nov 27:jnumed.120.256388. doi: 10.2967/jnumed.120.256388. Online ahead of print.

162. Brown JL, Sexton-Stallone B, Li Y, Frey EC, Treves ST, Fahey FH, Plyku D, Cao X, Choi C, Kim CH, Sgouros G, Aris JP, Bolch WE. Dosimetric considerations of 99m Tc-MDP uptake within the epiphyseal plates of the long bones of pediatric patients. Phys Med Biol. 2020 Dec 2;65(23):235025

163. De Silva RA, Gorin MA, Mease RC, Minn I, Lisok A, Plyku D, Nimmagadda S, Allaf ME, Yang X, Sgouros G, Rowe SP, Pomper MG. Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging

GS 8/27/2021 18 sgourosCV_2021_08-27

agent [ 111 In]In-XYIMSR-01 for phase I regulatory approval. J Labelled Comp Radiopharm. 2021 May 30;64(6):243-250. doi: 10.1002

164. Li Y, Chen J, Brown JL, Treves ST, Cao X, Fahey FH, Sgouros G, Bolch WE, Frey EC. DeepAMO: a multi-slice, multi-view anthropomorphic model observer for visual detection tasks performed on volume images. J Med Imaging (Bellingham). 2021 Jul;8(4):041204.

165. Prasad A, Nair R, Bhatavdekar O, Howe A, Salerno D, Sempkowski M, Josefsson A, Pacheco- Torres J, Bhujwalla ZM, Gabrielson KL, Sgouros G, Sofou S. Transport-driven engineering of liposomes for delivery of α-particle radiotherapy to solid tumors: effect on inhibition of tumor progression and onset delay of spontaneous metastases. Eur J Nucl Med Mol Imaging 2021 Jun 12. doi: 10.1007/s00259-021-05406-z. Online ahead of print. PMID: 34117896

166. Wahl RL, Frey EC, Jacene HA, Kahl BS, Piantadosi S, Bianco JA, Hammes RJ, Jung M, Kasecamp W, He B, Sgouros G, Flinn IW, Swinnen LJ. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin ®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers (Basel) 2021 Jun 6;13(11):2828

167. Plyku D, Ghaly M, Li Y, Brown JL, O'Reilly S, Khamwan K, Goodkind AB, Sexton-Stallone B, Cao X, Zurakowski D, Fahey FH, Treves ST, Bolch WE, Frey EC, Sgouros G. Renal 99mTc-DMSA pharmacokinetics in pediatric patients. EJNMMI Phys. 2021 Jul 20;8(1):53.

B. Books and Other Monographs

Books

1. Zaidi H, Sgouros G, Ed. Monte Carlo calculations in nuclear medicine: Therapeutic applications. Institute of Physics Publishing, 2002. 2. Sgouros G, Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

Chapters/Review Articles

1. Sgouros G, Scheinberg DA. The treatment of leukemia with radiolabeled monoclonal antibodies. In: Steven T. Rosen, Timothy M. Kuzel , Editors. Immunoconjugate Therapy of Hematologic Malignancies. Kluwer Academic Press, 23-64, 1993.

2. Sgouros G, Scheinberg DA. Treatment of leukemia with radiolabeled monoclonal antibodies. Cancer Treat Res 1993;68:23-64

3. Larson SM, Sgouros G, Cheung NKV. Monoclonal Antibodies in Cancer Therapy: Radioisotope conjugates. In: DeVita VT, Hellman S, Rosenberg SA, Editors. Biologic Therapy of Cancer (2nd Edition), Lippincott, 534-552, 1995.

4. Junghans RP, Sgouros G, Scheinberg DA. Antibody-based Immunotherapies for Cancer. In: Chabner B and Longo DL, Eds. Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd Edition, Lippincott, 655-689, 1996.

GS 8/27/2021 19 sgourosCV_2021_08-27

5. Larson SM, Sgouros G, Cheung NKV. Radiolabeled Antibodies: General Issues. In: Bertino J, Ed. Encyclopedia of Cancer, Academic Press, 1407-1431, 1996.

6. Sgouros G. Radioimmunotherapy of Micrometastases. In: Riva P, Ed. Cancer Radioimmunotherapy – Present and Future. Harwood Academic Publishers, 191-207, 1998.

7. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nuc Med, 25:1341-1351, 1998.

8. Larson SM, Divgi C, Sgouros G, Cheung NV, Scheinberg DA. Principles and Practice of Monoclonal Antibody Therapy:Radioisotope Conjugates. In:Rosenberg SA, Editor. Principles and Practice of the Biologic Therapy of Cancer, 3rd Edition, Lippincott, 396-412, 2000.

9. Scheinberg DA, Sgouros G, Junghans RP,. Antibody-based Immunotherapies for Cancer. In: Chabner B and Longo DL, Eds. Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd Edition, Lippincott, 850-860, 2001.

10. Sgouros G. Radiolabeled Antibodies: Overview. In: Bertino J, Ed. Encyclopedia of Cancer, 2nd Edition, Academic Press, 29-39, 2002.

11. Sgouros G, Yang W-H, Enmon R. Spheriods of Prostate Tumor Cell Lines. In: Jackson P, Russell P, Eds. Prostate Cancer: Methods and Protocols, The Humana Press, Inc., 2003.

12. Manuel B, Kwok C, Sgouros G. Dose point-kernels for radionuclide dosimetry. In: Zaidi H, Sgouros G, Ed. Monte Carlo calculations in nuclear medicine: Therapeutic applications. Institute of Physics Publishing, 158-174, 2002.

13. Sgouros G, Kolbert KS. The three-dimensional internal dosimetry software package, 3D-ID. In: Zaidi H, Sgouros G, Ed. Monte Carlo calculations in nuclear medicine: Therapeutic applications. Institute of Physics Publishing, 249-261, 2002.

14. Ljungberg M, Dewarja Y, Sgouros G, Strand S. Evaluation and validation of dose calculation procedures in patient-specific radionuclide therapy. In: Zaidi H, Sgouros G, Ed. Monte Carlo calculations in nuclear medicine: Therapeutic applications. Institute of Physics Publishing, 262-285, 2002.

15. Sgouros G. Dosimetric and radiobiological considerations: Patient-specific dosimetry. In: Peter Ell, Sanjiv S. Gambhir, Eds. Nuclear Medicine in Clinical Diagnosis and Treatment, Volume 1, 3rd Edition. Elsevier Science,375-382, 2004.

16. Sgouros G. Dosimetry of Internal Emitters. J Nucl Med 2005;46:18S-27S

17. Scheinberg DA, Mulford DA, Jurcic JG, Sgouros G, Junghans RP. Antibody therapies of cancer. In: Chabner BA, Longo DL, Eds. Cancer Chemotherapy and Biotherapy: Principles and Practice, 4th Edition, Lippincott Williams and Wilkins, 667-698, 2006.

18. Sgouros G, Knox SJ, Joiner MC, Morgan WF, Kassis AI. MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy? J Nucl Med 2007 Oct;48(10):1683-91.

GS 8/27/2021 20 sgourosCV_2021_08-27

19. Sofou S, Sgouros G. Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin Drug Deliv. 2008 Feb;5(2):189-204.

20. Sgouros G. Alpha particles for targeted therapy. Adv Drug Deliv Rev. 2008; 60(12):1402-6,

21. Sgouros G, Frey E, Wahl R, He B, Prideaux A, Hobbs R. Three-dimensional imaging-based radiobiological dosimetry. Semin Nucl Med 2008; 38(5):321-34.

22. Sgouros G. Update: molecular radiotherapy: survey and current status. Cancer Biother Radiopharm, 2008; 23(5):531-40.

23. Sgouros G. High-LET-Emitting Radionuclides for Cancer Therapy. In:Stigbrand T, Carlsson J, Adams GP, Eds. Targeted Radionuclide Tumor Therapy, Biological Aspects, Springer Sceince+Business Media B.V., 175-181, 2008.

24. Sgouros G. Radionuclides for Therapy. In: Pomper MG, Gelovani JG., Eds. Molecular Imaging in Oncology, Informa Healthcare USA, 217-226, 2008.

25. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H, Howell RW, Akabani G. MIRD Pamphlet No. 22 (abridged) - Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med, 2010 Feb;51(2):311-28. Epub 2010 Jan 15

26. Song H, Sgouros G. Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv. 2011 Jan 1;8(1):26-44.

27. Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, Wahl RL. Three- dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S41-7. Epub 2011 Apr 12

28. Sgouros G, Hobbs RF, Song H. Modelling and dosimetry for alpha-particle therapy. Curr Radiopharm. 2011;4:261-5.

29. Meghzifene A, Sgouros G. IAEA support to medical physics in nuclear medicine. Semin Nucl Med. 2013 May;43(3):181-7.

31. Sgouros G, Hobbs RF. Patient-Specific Dosimetry, Radiobiology, and the Previously-Treated Patient. In: MEDICAL RADIOLOGY – Radiation Oncology, Edited by L.W. Brady, H.-P. Heilmann, M. Molls, C. Nieder. Volume: Therapeutic Nuclear Medicine – Edited by Richard P. Baum 2014

32. Sgouros G, Hobbs RF. Dosimetry for Radiopharmaceutical Therapy. Semin Nucl Med, 2014 May;44(3):172-8.

33. Brill AB, Sgouros G, Introduction. Sgouros G, Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

GS 8/27/2021 21 sgourosCV_2021_08-27

34. Brill AB, Fisher DR, Sgouros G, Historical Overview. Sgouros G, Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

35. Allen BJ, Hobbs RF, Howell RW, Sgouros G, Song H. Alpha-Particle Radiobiology, Sgouros G, Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

36. Hobbs RF, Howell RW, Sgouros G, Song H. Relative Biological Effectiveness. Sgouros G, Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

37. Allen BJ, Hobbs RF, Roeske JC, Fisher DR, Sgouros G Alpha-Particle Dosimetry. Sgouros G, Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

38. Allen BJ, McDevitt MR, Meredith RF, Palm S, Sgouros G, Torgue J, Zalutsky MR. Alpha- Particle Emitters of Interest for Human Use. Sgouros G, Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

39. Howell RW, Sgouros G. Dosimetry Recommendations for Deterministic Effects. Sgouros G, Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceuical Therapy with Alpha-Particle Emitters Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

40. Sgouros G. Summary. Sgouros G, Ed. MIRD Monograph- Radiobiology and Dosimetry for Radiopharmaceutical Therapy with Alpha-Particle Emitters. Society of Nuclear Medicine and Molecular Imaging Publishing, 2014

41. Fahey FH, Goodkind AB, Plyku D, Khamwan K, O’Reilly SE, Cao X, Frey EC, Li Y, Bolch WE, Sgouros G, Treves ST. Dose Estimation in Pediatric Nuclear Medicine, Seminars in Nuclear Medicine, Available online 9 November 2016, ISSN 0001-2998, http://dx.doi.org/10.1053/j.semnuclmed.2016.10.006

42. McDevitt MR, Sgouros G, Sofou S. Targeted and Nontargeted α-Particle Therapies. Ann Rev Biomed Eng 2018; 20:1.

43. Sgouros G, Hobbs R, Josefsson A. Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides. Curr Radiopharm. 2018;11(3):209-214.

44. Sgouros G. Radiopharmaceutical Therapy. Health Phys. 2019 Feb;116(2):175-178

46. Morris MJ, Corey E, Guise TA, Gulley JL, Kevin Kelly W, Quinn DI, Scholz A, Sgouros G. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol. 2019 Dec;16(12):745-756

48. Sgouros G. α-Particle-Emitter Radiopharmaceutical Therapy: Resistance Is Futile. Cancer Res. 2019 Nov 1;79(21):5479-5481

GS 8/27/2021 22 sgourosCV_2021_08-27

47. Sgouros G. Dosimetry, Radiobiology and Synthetic Lethality: Radiopharmaceutical Therapy (RPT) With Alpha-Particle-Emitters. Sem Nuc Med 2020 50(2):124-132

48. Roncali E, Capala J, Benedict SH, Akabani G, Bednarz B, Bhadrasain V, Bolch WE, Buchsbaum J, Clarke BN, Coleman N, Dewaraja YK, Frey EC, Ghaly M, Grudzinski J, Hobbs RF, Howell RW, Humm JL, Kunos C, Larson SM, Lin FI, Madsen MT, Mirzadeh S, Morse DL, Pryma DA, Sgouros G, St James S, Wahl RL, Xiao Y, Zanzonico PB, Zukotynski KB. Overview of the First NRG-NCI Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy (RPT). J Nucl Med. 2020 Dec 4:jnumed.120.255547. doi: 10.2967/jnumed.120.255547. Online ahead of print.

49. Divgi C, Carrasquillo JA, Meredith R, Seo Y, Frey EC, Bolch WE, Zimmerman BE, Akabani G, Jacobson DA, Brown B, Davern SM, Hobbs RF, Humm J, Moros EG, Morse D, Papineni R, Zanzonico P, Benedict SH, Sgouros G. Overcoming Barriers to Radiopharmaceutical Therapy: An Overview from the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy (RPT). Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):905- 912. 50. Xiao Y, Roncali E, Hobbs R, James SS, Bednarz B, Benedict S, Dewaraja YK, Frey E, Grudzinski J, Sgouros G, Buchsbaum JC, Capala J. Toward Individualized Voxel-Level Dosimetry for Radiopharmaceutical Therapy. Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):902-904

C. Other

Conference Proceedings

1. Bigler RE, Sgouros G. Radiation Dosimetry of 15O-labeled O , CO , and CO gases 2 2 administered continuously in the breath. Nuclear Medicine and Biology, Vol II, p. 2000-2003, C. Raynaud, Ed. Pergamon Press, New York, 1982.

2. Bigler RE, Zanzonico PB, Cosma M, Sgouros G. Adjuvant radioimmunotherapy for micrometastases: A strategy for cancer cure. In Radiolabeled Antibodies for Imaging and Therapy, NATO Advanced Study Institute, Barga, Italy, July 20 - August 1, 1986. Srivastava SC (Ed), Plenum Press, New York, pp 409-429, 1988.

3. Zanzonico PB, Bigler RE, Sgouros G, Strauss A. Quantitative SPECT in radiation dosimetry. Sem Nucl Med 19:47-61, 1989.

4. Zanzonico PB, Edwards C, Sgouros G, Strauss A, Bigler RE, Hurley JR, Becker DV. Practical dosimetry: Quantitative imaging in radionuclide therapy. In: Dosimetry of Administered Radionuclides. Eds: Adelstein SJ, Kasis AI, Burt RW. American College of Nuclear Physicians and Society of Nuclear Medicine. Washington DC, 1989. p 275-294

5. Fisher DR, Sgouros G. Dosimetry of radium-223 and progeny. Proceedings of the 6th International Radiopharmaceutical Dosimetry Symposium, May 7-10, 1996, Gatlinburg, TN; Pgs. 375-391.

GS 8/27/2021 23 sgourosCV_2021_08-27

6. Behr TM, Sgouros G, Sharkey RM, Dunn RM, Blumenthal RD, Kolbert KS, Juweid ME, Siegel JA, Goldenberg DM. 90Y-Dosimetry in the nude mouse: Evaluation of three dosimetry models in relation to the observed biological effects in the radioimmunotherapy of human colon cancer xenografts. Proceedings of the 6th International Radiopharmaceutical Dosimetry Symposium, May 7-10, 1996, Gatlinburg, TN.

7. Sgouros G. Treatment planning for internal emitter therapy: Methods, applications and clinical implications. Proceedings of the 6th International Radiopharmaceutical Dosimetry Symposium, May 7-10, 1996, Gatlinburg, TN; pgs. 13-24.

8. Sgouros G. Alpha Particle Emitters in Cancer Therapy: Establishing the Rationale and Overcoming the Difficulties. Proceedings of EPSMH '96, Engineering & the Physical Sciences in Medicine & Health Conference, October 21-24, 1996, Canberra, Australia.

9. Sgouros G. Internal Emitter Dosimetry: Are Patient-Specific Calculations Necessary? Proceedings of EPSMH '96, Engineering & the Physical Sciences in Medicine & Health Conference, October 21-24, 1996, Canberra, Australia.

10. Sgouros G. Mathematical Models of Tumour Growth: Translating Absorbed Dose to Tumour Control Probability Proceedings of EPSMH '96, Engineering & the Physical Sciences in Medicine & Health Conference, October 21-24, 1996, Canberra, Australia.

11. Larson SM, El-Shirbiny AM, Divgi CR, Sgouros G, Finn RD, Tschmelitsch J, Picon A, Whitlow M, Schlom J, Zhang J, Cohen AM. Single chain antigen binding protein (sFv CC 49): First human studies in colorectal cancer metastatic to liver. Cancer 1997;80(12 Suppl):2458-2468

12. Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert KS, Griffiths GL, Siegel JA, Becker WS, Goldenberg DM. Overcoming nephrotoxicity of radiometal-labeled immunoconjugates: Improved cancer therapy in a nude mouse model in relation to the internal radiation dosimetry. Cancer 1997; 80(12 Suppl):2591-2610.

13. Sgouros G. Introduction to kidney dose-response for radionuclide therapy. Cancer Biother Radiopharm 2004; 19:357 In: Sgouros, G. Wessels B., Guest Editors. Kidney Dose-Response for Radionuclide Therapy. Cancer Biother Radiopharm 2004; 19:355-390.

14. Sgouros G, Hobbs RF, Abou DS. The role of preclinical models in radiopharmaceutical therapy. Am Soc Clin Oncol Educ Book. 2014:e121-5. 10.14694/EdBook_AM.2014.34.e121

15. Sgouros G. The Case for Dosimetry in Alpha-Emitter Therapy. J Med Img Rad Sci 2019, 50(4);S45-S46.

Editorial/Commentary

1. DeNardo GL, Maddock SW, Sgouros G, Scheibe PO, DeNardo SJ. Immunoadsorption: An enhancement strategy for radioimmunotherapy. J Nucl Med 1993; 34:1020-1027.

2. Sgouros G. Radioimmunotherapy of micrometastases: Side-stepping the solid tumor hurdle. J Nucl Med 1995; 36:1910-1912.

GS 8/27/2021 24 sgourosCV_2021_08-27

3. Zanzonico P, Sgouros G. Prediction of myelotoxicity in radioimmunotherapy: What does dosimetry contribute? J Nucl Med 1997; 38:1753-1754.

4. Sgouros G. Long-lived Alpha Emitters in Radioimmunotherapy: The Mischievous Progeny. Cancer Biother & Radiopharm 2000; 15:219-221.

5. Behr TM, Behe M, Jungclas H, Jungclas H, Becker W, Sgouros G. Higher relative biological efficiency (RBE) of alpha-particles for acute effects: in vitro veritas, in vivo vanitas? Eur J Nucl Med 2001; 28:1435-6.

6. Sgouros G. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer J Nucl Med 2005; 46:899-900.

7. Sgouros G. Towards patient-friendly cell-level dosimetry. J Nucl Med 2007; 48:496-497.

8. Sgouros G. Molecular radiotherapy: Targeting cancer at the cellular level. MI Gateway, Newsletter of the SNM Molecular Imaging Center of Excellence. J Nucl Med 2007, Dec issue.

9. Sgouros G. Update: molecular radiotherapy: survey and current status Cancer Biother Radiopharm 2008; 23(5):531-540

10. Sgouros G, Howell RW, Bolch WE, Fisher DR. MIRD Commentary: Proposed Name for a Dosimetry Unit Applicable to Deterministic Biological Effects--The Barendsen (Bd). J Nucl Med 2009; 50(3):485-487.

11. Wessels BW, Dale RG, Cremonesi M, Meredith RF, Green AJ, Brill B, Bolch WE, Sgouros G, Thomas SR. Renal Dosimetry. Cancer Biother Radiopharm. 2010 Oct;25(5):597-9.

12. Sgouros G, Goldenberg DM. Radiopharmaceutical therapy in the era of precision medicine, Eur J Cancer. 2014 Sep;50(13):2360-3

13. Van Nostrand, D., Hobbs, R., Atkins, F.B. and Sgouros, G., 2016. 124I in Differentiated Thyroid Cancer. In Thyroid Cancer (pp. 973-989). Springer New York

14. Sgouros G. α-Particle-Emitter Radiopharmaceutical Therapy: Resistance Is Futile. Cancer Res. 2019 Nov 1;79(21):5479-5481

Media/interviews http://www.cbsnews.com/news/a-new-frontier-in-the-war-on-cancer-4121081/

GS 8/27/2021 25 sgourosCV_2021_08-27

Patents and Software Copyrights

Parametric Image Representation of Imaging Agent Kinetics US5684889A. Alpha-Emitting Constructs & Uses Thereof WO1999061097A9 Liposomal Encapsulation of Alpha-Particle Emitters and uses thereof US 2003O175206A1 Analysis and Display Software for Multi-Modality, Longitudinal Imaging Studies: Multi- Modality Image Analysis Utility (MIAU)," Copyright filed February 8, 2002 Use of Histone Deacetylase Inhibitors in Combination with Radiation for the Treatment of Cancer 60/373,033 System and Method for Determining Amount of Radioactive Material to Administer to a Patient WO 2008/079569 A3 Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen WO 2009/111088 A2 Combination Therapy for the Treatment of Cancer WO2003088954A1 Method and System for Gamma Camera Countrate Saturation Correction US 2011/0176018 A1 Method and System for Administering Internal Radionuclide Therapy (IRT) and External Radiation Therapy (XRT) US20110135058A1 Method and System for Administering Radiopharmaceutical Therapy (RPT) US20130165732A1 Prevention of Systemic Toxicity During Radioimmunotherapy for Intravascularly Disseminated Cancers US20040141916A1 Intraductal Delivery of Targeted Alpha-Particle, Beta-Particle or Auger Electron-Emitters for Treatment of Breast Cancer WO2017062394A1

Research Support (PI or Co-PI)

Active

Title: R01CA187037 “Combined Biologic and Radiopharmaceutical Therapy of Breast Cancer” Time Commitment: .3 calendar months Supporting Agency:NIH/NCI – (Sgouros – PI) Performance Period: 05/01/2015 – 04/30/2022

GS 8/27/2021 26 sgourosCV_2021_08-27

Level of Funding/total per year: $459,386 Project Goal: Perform pre-clinical studies to make alpha-emitter radiopharmaceutical therapy, in combination with biological response modifiers an effective alternative to chemotherapy and pathway inhibition therapy in patients with metastatic cancer Specific Aims: 1. Identify αRPT/BRM combinations that lead to the greatest tumor cell kill, in vitro. 2. Assess pharmacokinetics, efficacy and toxicity of the αRPT/BRM combinations identified in Aim 1 for further study. 3. Develop a pharmarcokinetic/dosimetry model to fit response/toxicity data obtained in Aims 1 and 2.

Title: R01CA116477 “Dose Response in Radionuclide Therapy” Time Commitment: .2.4 calendar months Supporting Agency:NIH/NCI – (Sgouros – PI) Performance Period: 5/1/2006 - 6/30/2023 Level of Funding/ total per year: $668,984 Project Goal: The project goal is to develop and test dosimetry methodologies and software; applicable to radiopharmaceutical therapy Specific Aims: Evaluate RBE for tumors and normal organs, develop and implement microscale dosimetry methods applicable to patient dosimetry of alpha-RPTs

Title: 1R01EB013558 Dose Reduction in Pediatric Molecular Imaging Time Commitment: 2.4 Calendar months Supporting Agency: NIBIB (Sgouros, Frey –PI) Performance Period: 03/01/2012 – 06/30/2022 Level of Funding/ total per year: $661,222 Project Goal: The objective of this proposal is to develop and validate techniques that can be used to reduce the radiation exposure to pediatric patients undergoing molecular imaging procedures using methods that retain the diagnostic quality of the images.

Title: Treatment optimization by combined alpha-emitter (alphaRPT)/radiotherapy (XRT) dosimetry for prostate cancer patients Time Commitment: 0.6 Calendar months Supporting Agency: Hopkins subcontract to NIH/NCI Contract No. 75N91019C00040 awarded to Radiopharmaceutical Imaging and Dosimetry, LLC (Rapid), (Sgouros–PI of Hopkins sub-contract) Performance Period: 10/01/2019 – 09/30/2022 Level of Funding: $303,329 Project Goal: Demonstrate value of incorporating radiopharmaceutical dose map in radiotherapy treatment planning of patients previously administered Ra-223.

Title: R01 CA240779 Combination Radiopharmaceutical Therapy and External Beam Radiotherapy Time Commitment: 1.2 Calendar months Supporting Agency: NIH/NCI (MPI: Hobbs, Ladenson, Sgouros (corresponding)) Performance Period: 04/01/2020 – 03/31/2025 Level of Funding/ total per year: $ 698,167 Project Goal: Assess feasibility and response to thyroid Ca patient, dosimetry-driven treatment planning-based combination radioiodine and XRT therapy.

Title: U01 EB031798 High Energy and Spatial Resolution Multi-Isotope SPECT Imaging of Targeted Alpha-Emitters and their Daughters. Time Commitment: 1.2 Calendar months

GS 8/27/2021 27 sgourosCV_2021_08-27

Supporting Agency: NIH/NIBIB (MPI: Du, Frey, Meng, Sgouros (corresponding),) Performance Period: 04/01/2020 – 03/31/2025 Level of Funding/ total per year: $ 755,547 Project Goal: Build and evaluate a next-generation SPECT to support alpha-emitter radiopharmaceutical therapy of cancer.

Pending

Title: R21 CA256427 Alpha-particle nanotherapeutics against chemoresistant Triple Negative Breast Cancer Time Commitment: 0.12 Calendar months Supporting Agency: NIH/NCI (Sofou, PI; Sgouros, MPIs) Performance Period: 12/01/2020 – 11/30/2022 Level of Funding/ total per year: $ 245,625 Project Goal: Assess feasibility and response of engineered, multifunctional spheroids to deliver alpha-emitters and treat chemoresistant BCa.

5/1/92 - 4/30/93 Pilot-Mechanisms of Radiation Induced Activation of the Pentose Phosphate Pathway in Rat Brain NIH P01-CA29502 (sub-project) PI (of P01): Richard Rivlin Total direct costs:, $10,800 Role:PI of sub-project

10/1/92 - 9/30/96 Radioimmunotherapy of CML NIH U01-CA58260 PI: David A. Scheinberg Role: Leader, Modeling and Dosimetry

4/1/95 – 3/31/03 Modeling and Dosimetry for Radiolabeled Antibody Therapy NIH R01-CA62444 Total direct costs: $2,319,458 Role: PI

6/14/95 - 6/14/97 Pharmacokinetics of Genetically Engineered Ab forms using PET DOE 94-015 PI: Steven M. Larson Role: Co-Inv

7/1/97 – 4/30/01 Antibody Therapy of Micrometastases NIH R01 CA72683 Total direct costs: $674,253 Role: PI

1/1/00-12/31/04 Biological Approaches to the Treatment of

GS 8/27/2021 28 sgourosCV_2021_08-27

Cancer; Biophysics/Nuclear Medicine Core NIH/NCI P01 CA33049 Total direct costs: $686,500 (Core) PI: Alan Houghton Role: Co-PI of Core

3/1/00-3/1/03 NIH/NCI (P50) RFA CA-99-004 In Vivo Cellular and Molecular Imaging Centers (ICMICs); Imaging Spheroid Growth and Vascularization, In Vivo PI: Ronald Blasberg/Steven Larson Role: PI of sub-project

11/1/00-10/31/03 Radiolabeled Herceptin to Increase Treatment Efficacy in Breast Cancer Patients with Low Tumor HER2/neu Expression Army Breast Cancer Research Program – Idea Award BC990927total direct costs: $361,375 Role: PI

12/1/00-11/31/02 Targeted Delivery of Alpha Particle-Emitting Radionuclides and Their Alpha-Emitting Progeny: Breast Cancer Therapy Using Liposome- Encapsulated Alpha-Emitters Army Breast Cancer Research Program – Concept Award BC996563 Total direct costs: $83,250 Role: PI

1/1/01-12/31/02 Combined Targeted Radionuclide Therapy and Chemotherapy of Prostate Cancer CaP CURE Award Total direct costs:, $100,000 Role: PI

5/1/03 – 1/31/07 Advances in Skeletal Dosimetry Through Microimaging NIH R01 CA096441 PI Wesley Bolch, U. Florida Total direct costs $52,656 Role: PI of sub-contract

9/30/03-10/31/06 Therapy of Ovarian Carcinoma by Targeted Delivery of Alpha-Particles using Immunoliposomes Capable of Retaining Alpha- Emitting Daughters DOD OCRP – IDEA Award DOD OC02009 Total direct costs: $355,222 Role: PI

12/1/04-11/30/07 Patient-Specific Dosimetry and Radiobiological Modeling of Targeted Radionuclide Therapy

GS 8/27/2021 29 sgourosCV_2021_08-27

Department of Energy, Office of Science (BER), - Grant No. DE-FG02-05ER63967 Total direct costs: $226,611 (funding terminated after 6 mos because DOE program supporting grant was eliminated) Role: PI

2/9/05-11/30/09 Targeted Alpha-Particle Therapy of Metastases NIH/NCI R01 CA113797 Total direct costs: $700,000 Role: PI

3/1/05-2/28/08 Combination Treatment of Her2/Neu Expressing Breast Cancer Metastasis by Targeted Alpha- Particle Radioimmunotherapy And Cancer Vaccine DOD BCRP USARMC W81XWH05010290– Multidisciplinary Fellowship Total direct costs $368,786 PI: Hong Song Role: Mentor, 10 % effort (no salary)

7/1/06-6/30/07 Enhanced Anti-Tumor Immunization by Liposomal Delivery of Vaccine to the Spleen DOD BCRP –USAMRMC Concept Award BC052595 Total direct costs: $75,000 Role: PI

7/1/06 – 6/30/09 Liposomal Delivery of High LET Emitters to Cell Nuclei Ruth L. Kirstein National Research Service Award (NRSA) 1F32CA12365 -Fellowship in Nanotechnology for Medicine Total direct costs: $143,000 PI: Yah-el Har-el Role: Mentor, 5% effort (no salary)

5/10/2012 - 4/30/2017 Modeling Targeted Alpha Particle Therapy of Cancer NIH/NCI $254,201 PI: Robert Hobbs Role: Co-PI, 10%

09/15/2011 - 07/3/2017 Quantitative SPECT for Targeted Radionuclide Therapy R01 CA109234 PI: Eric Frey Role: Co-Inv, 3%

GS 8/27/2021 30 sgourosCV_2021_08-27

6/1/13 – 3/31/18 Combination External Beam Radiotherapy with 153Sm-EDTMP to Treat High Risk Osteosarcoma NIH $207,500 PI: David Loeb Role: MPI, 5%

09/22/2011- 07/31/2016 JHU ICMIC Program NIH/NCI $890,668 PI: Zaver Bhujwalla Role: Co-Inv, 2%

08/09/2012 – 04/30/2017 Regional Oncology Research Center NIH/NCI $1,009,348 PI: William Nelson Role: Co-Inv, 1%

09/01/13 – 08/31/18 SPORE in Prostate Cancer Time Commitment: .6 (Co-Inv) Supporting Agency: NCI PI: Nelson Performance Period: Level of Funding: $1,563,772

04/01/14 – 03/31/2019 Title: R01CA184228 Small Molecule PSMA- Targeted Alpha Therapy Time Commitment: .6 Supporting Agency: NIH PIs: Pomper, Sgouros, Zalutsky Performance Period: 04/01/14 – 03/31/2019 Level of Funding: $412,893 Project Goals and Specific Aims: Major goals of TAT and this proposal are to show that the LMW agents we propose will enable high tumor penetration and limit toxicity to normal tissues

GS 8/27/2021 31 sgourosCV_2021_08-27

Clinical Trials Absorbed dose vs Response Database in 5/29/2014 IRB00038617 Terminated Sgouros

Radiopharmaceutical Therapy 1:06 PM Phase 1 Biodistribution and Pharmacokinetic 10/23/2015 IRB00067243 Approved Jain

Study of 11C-Rifampin PET in TB patients. 4:57 PM Generation of Stably expressing luciferase Researcher 10/27/2016 IRB00119623 Sgouros

cell line. Prep 3:25 PM Dose Reduction in Pediatric Molecular Researcher 3/15/2017 IRB00132697 Sgouros

Imaging Prep 3:30 PM Biokinetics Study for Dose Reduction in 4/27/2017 IRB00135751 Approved Sgouros

Pediatric Molecular Imaging 11:53 AM A Dose Finding Study of CycloSam® (153Sm-DOTMP) Combined with External 1/29/2018 IRB00137081 Beam Radiotherapy to Treat High Risk Withdrawn Loeb 1:01 AM Osteosarcoma and Other Solid Tumors

Metastatic to Bone Personalized Treatment Planning for Radio- 7/19/2018 IRB00157150 Approved Santhanam

iodine Therapy of Thyroid Disease 5:46 PM A Phase I/II Study of 131I-Tositumomab in 9/14/2013 NA_00005743 Patients with Relapsed/Refractory Hodgkin’s Expired Wahl 8:13 PM

Lymphoma Phase 1 Biodistribution and Pharmacokinetic 9/14/2013 NA_00019359 Study of 18F-DCFBC PSMA based PET in Expired Cho 10:51 PM

Patients with Advanced Prostate Cancer 9/14/2013

NA_00023048 F-18-FBnTP PET imaging in healthy subjects Expired Madar 9:38 PM Imaging of Viral Thymidine Kinase Activity in 9/14/2013 NA_00032681 EBV-Associated and KSHV-Associated Terminated Ambinder 9:11 PM

Malignancies 9/15/2013

NA_00052286 PET imaging of mitochondria function Expired Madar 12:02 AM Combination of External Beam Radiotherapy with 153Sm-EDTMP to Treat High Risk 9/14/2013 NA_00075773 Approved Ladle Osteosarcoma and Patients with Solid 2:05 PM Tumors Metastatic to Bone Validation of Dose Estimation Methods and Measurement of Normal Liver Dose in Y-90 9/14/2013 NA_00077479 Approved Frey Therasphere Therapy with Quantitative 9:03 PM Nuclear Imaging Phase 1 Biodistribution and Pharmacokinetic Study of 124I-DPA-713 translocator protein 6/25/2014 NA_00092484 (TSPO) based PET in Normal Human Approved Jain 3:00 PM Volunteers and Feasibility Study for Detection of Tuberculosis. NA_00092956 Study of 18F-DCFPyL, a Second Generation Approved 5/16/2014 Rowe

GS 8/27/2021 32 sgourosCV_2021_08-27

low-molecular weight PSMA-based PET 10:07 AM radiotracer, in Patients with Prostate Cancer

Validation of Dose Estimation Methods Continuing Review: and Measurement of Normal Liver Dose 2/21/2014 CR00000170 For: Approved Geschwind in Y-90 Therasphere Therapy with 11:06 AM

NA_00077479 Quantitative Nuclear Imaging Continuing Review: A Phase I/II Study of 131I-Tositumomab 4/7/2014 CR00000808 For: in Patients with Relapsed/Refractory Approved Wahl 2:31 PM

NA_00005743 Hodgkin’s Lymphoma Combination of External Beam Continuing Review: Radiotherapy with 153Sm-EDTMP to 4/25/2014 CR00000800 For: Treat High Risk Osteosarcoma and Approved Loeb 2:46 PM

NA_00075773 Patients with Solid Tumors Metastatic to Bone Continuing Review: F-18-FBnTP PET imaging in healthy 8/18/2014 CR00002390 For: Approved Madar subjects 11:09 AM

NA_00023048 Continuing Review: Imaging of Viral Thymidine Kinase 10/20/2014 CR00002943 For: Activity in EBV-Associated and KSHV- Approved Kasamon 4:15 PM

NA_00032681 Associated Malignancies Continuing Review: 11/3/2014 CR00002950 For: PET imaging of mitochondria function Approved Madar 3:36 PM NA_00052286 Validation of Dose Estimation Methods Continuing Review: and Measurement of Normal Liver Dose 2/26/2015 CR00004814 For: Approved Geschwind in Y-90 Therasphere Therapy with 12:01 PM NA_00077479 Quantitative Nuclear Imaging Combination of External Beam Continuing Review: Radiotherapy with 153Sm-EDTMP to 4/10/2015 CR00005177 For: Treat High Risk Osteosarcoma and Approved Loeb 11:06 AM NA_00075773 Patients with Solid Tumors Metastatic to Bone Continuing Review: A Phase I/II Study of 131I-Tositumomab 4/10/2015 CR00005510 For: in Patients with Relapsed/Refractory Approved Wahl 11:08 AM NA_00005743 Hodgkin’s Lymphoma Study of 18F-DCFPyL, a Second Continuing Review: Generation low-molecular weight PSMA- 4/16/2015 CR00004969 For: Approved Szabo based PET radiotracer, in Patients with 4:36 PM NA_00092956 Prostate Cancer

GS 8/27/2021 33 sgourosCV_2021_08-27

Teaching

Imaging Physics Lecture and Problem Course, MSKCC 1995-2003 – “Radionuclides for Nuclear Medicine,” “Single-Photon Emission Computed Tomography (SPECT),”

Physics Lectures for Nuclear Medicine Residents and Fellows, MSKCC 1995-2003 – “Introcution to Tracer Kinetic Modeling,” “Internal Radionuclide Radiation Dosimetry”

Lectures for Nuclear Medicine Residents and Fellows, Johns Hopkins University, School of Medicine, Radiology 2003-2005 – “Internal Radionuclide Radiation Dosimetry,” “Introduction to Radiobiology I and II”

“Modern Biomedical Imaging Instrumentation and Techniques” Johns Hopkins University Engineering School course: ECE 520.434/ BME 580.472, Radiation Dosimetry/Radiobiology lecture 2009-

"Modeling and Dosimetry of Radiolabeled Antibody Therapy" Seminar in Medical Physics, Columbia University, Dept. of Applied Physics, New York NY, 1995

“Dosimetry and Treatment Planning for Radioimmunotherapy: Future Directions” Refresher Course, Annual Meeting of the American Association of Physicists in Medicine, Boston, MA, 1995

"Radioimmunotherapy of Micrometastases: Alpha Particle Targeting of Multicellular Spheroids" Columbia University, Seminar in Medical Physics, Dept. of Applied Physics, New York NY, 1998

"Dosimetry of Alpha Particles in Pre-Clinical and Clinical Studies" Categorical Seminar, Speaker Annual Meeting, Society of Nuclear Medicine, St. Louis MO, 2000.

“Kidney Dose-Response for Radionuclide Therapy” Continuing Education Session, Organizer/Moderator, Society of Nuclear Medicine New Orleans, LO 2003

“Bystander and low-dose rate effects” Continuing Education Session, Organizer/Moderator, Society of Nuclear medicine San Diego, CA 2006

“Update on Dosimetry-Based Techniques in Thyroid Cancer” CME course: Nuclear Oncology from Genotype to Targeted Radionuclide Therapy Johns Hopkins University, Baltimore MD March 2008

“Targeted Therapy with Alpha-Particle Emitters - Dosimetry” CME course: Nuclear Oncology from Genotype to Targeted Radionuclide Therapy Johns Hopkins University, Baltimore MD March 2008

“Quantities and Units related to Deterministic Effects” CME Course, Society of Nuclear Medicine, Annual Meeting

GS 8/27/2021 34 sgourosCV_2021_08-27

San Antonio, TX 2011

“Dosimetry, Radiobiology in Radiopharmaceutical Diagnosis and Therapy (i.e., nuclear medicine)” e-Radiology Physics Lecture Series, Johns Hopkins University, Baltimore MD May 2012

“Future Directions for Individualized Pediatric Dosing Guidance” MIRD CME Course, Society of Nuclear Medicine, Annual Meeting Miami FL June 2012

“Quantifying Patient Risk in RIB Protocols and Clinical Trial Design” MIRD CME Course, Society of Nuclear Medicine and Molecular Imaging, Annual Meeting Miami FL June 2012

Radiobiology and Dosimetry of Alpha-Particle Emitter Therapy” CME: Course, Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, St. Louis MO June 2014

ICMIC lecture, “Prospects for Combination Radiopharmaceutical Therapy” Dept of Radiology, Johns Hopkins University, School of Medicine Baltimore MD, September 2014

Johns Hopkins University, School of Medicine Translational Research Conference, “Radioactive Pharmaceuticals that Target Cancer Cells-A Different Type of Targeted Biologic Therapy” Baltimore MD, October 2014

Mentoring

John D. Willins, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics Co-advisor (w/ Clift Ling, Ph.D., MSKCC); ‘93–‘94, 1st prize Young Investigator, AAPM, 2000 Present position: Chief Medical Physicist, Dept. of Rad. Onc., Boston Medical Center, Boston, MA

Eli E. Furhang, Columbia University Grad Student, Applied Physics Co-Ph.D. Advisor (w/ Chen Chui, Ph.D., MSKCC); ‘95-‘97, Ph.D. awarded in ‘97 Present position: Physics Director, Beth-Israel Medical Center, New York, NY

Åse M. Ballangrud, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics Advisor 6/97 – 8/00, received Army IDEA award in 2000 Present position: Associate Attending Physicist, Associate Member, Medical Physics, MSKCC, New York, NY

Klaus A. Hamacher, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics Advisor 12/97 – 5/01, Present position: Medical Physicist, Columbia University, New York, NY

GS 8/27/2021 35 sgourosCV_2021_08-27

Stig Palm, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics Advisor 3/01 – 3/03, 1st prize, Med Phys young investigator NY RAMPS, 2002 Present position:Prof. Dept. of Radiation Physics, Göteborg University, Sweden.

Richard Enmon, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics Advisor 6/01 – 3/03, Present position: Associate in the Intellectual Property Group, King & Spalder, New York.

Stavroula Sofou, Post-doctoral fellow, Mem. Sloan-Kettering Cancer Ctr, Medical Physics Advisor 10/01 – 3/03, Graduate Research Grant, Hellenic Univ. Club of New York Present position: Assoc. Prof., Dept of Biomed Engineering, Johns Hopkins University

Hong Song, Post-doctoral fellow, Johns Hopkins University, School of Medicine, Radiology Awarded Multidisciplinary Post-Doctoral Fellowship Award from Department of Defense Breast Cancer Research Program (BCRP). Titled: “Combination Treatment of HER2/neu Expressing Breast Cancer Metastasis by Targeted alpha-Particle Radioimmunotherapy and Cancer Vaccine”. Promoted to Research Associate in 2008 Received an exploratory grant award, “Targeting metastatic pancreatic cancer stem cells by alpha particle radiation” from the Maryland Stem Cell Research Fund in 2009, 7/1/2009-6/30/2011, 207k direct. Assist Prof., Dept of Radiology, Johns Hopkins University, School of Medicine Advisor 12/03 – 6/09 Present position: Medical Fellow in Nuclear Medicine, Stanford University

Yah-el Har-el, Post-doctoral fellow, Johns Hopkins University, School of Medicine, Radiology Awarded the Ruth L. Kirstein National Service Award Fellowship (NIH), Project title: “Liposomal Delivery of High LET Emitters to Cell Nuclei” Advisor 6/05 – 12/09 Present position: Assistant Professor, Bioengineering, Temple University, College of Engineering

Andrew Prideaux, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology Advisor 5/05 –6/08 Present position: Clinical Applications Specialist, Hermes Medical Solutions, Stockholm, Sweden

Mohanambe Lingappa, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology Awarded the Multidisciplinary Post-Doctoral Fellowship Award from the Department of Defense Breast Cancer Research Program (BCRP), Project title: “Anti-tumor immunization by liposomal delivery of vaccine to the spleen” Advisor 4/06 –2010

Robert Hobbs, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology Advisor 5/06 –2012, received NIH R01 grant, “Modeling Targeted Alpha Particle Therapy of Cancer” in 2012. Present position: Asssociate Professor, Johns Hopkins University, SOM, Radiation Oncology

Sebastien Baechler, Visiting fellow, University Institute of Radiation Physics, Lausanne University, Lausanne, Switzerland. Recipient of a Swiss National Science Foundation:

GS 8/27/2021 36 sgourosCV_2021_08-27

fellowship No. PBFR2-115886. Advisor 3/07-3/08

Wietske van der Weg, Visiting fellow, Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Advisor 9/11-11/11

Senthamizhchelvan Srinivasan, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology, Recipient first place, Young Investigator Award, Society of Nuclear Medicine and Molecular Imaging. Advisor 10/08 –7/12 Present position: Chief Medical Physicist, Memorial Health Nashville TN

Donika Plyku, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology Advisor 8/12 –5/17 Present position: Research Associate, Division of Nuclear Medicine, Johns Hopkins University, SOM, Radiology Present position: Senior Staff Fellow. Division of Imaging and Radiation Medicine. Office of Specialty Medicine. Office of New Drugs (OND). CDER | US FDA

Sagar Ranka, Visiting Medical Student, Lokmanya Tilak Municipal Medical College, India Research Elective Mentor 4//14 – 6/14 Post-doctoral fellow 9//15 – 4/16 Present position: Medical Fellow Rush Medical School, Chicago IL

Anders Josefsson, Post-doctoral fellow, Johns Hopkins University, SOM, Radiology, Advisor 1/14-6/18 Research Associate, Division of Radiological Physics 6/18-12/20 Present position: Instructor University of Pittsburgh, Hillman Cancer Center

Fabien Jammes, intern, 7/14-9/14

Kitiwat Khamwan, Ph.D., Post-doctoral fellow, Johns Hopkins University, SOM, Radiology, Recipient first place, Young Investigator Award, Society of Nuclear Medicine and Molecular Imaging Advisor 1/15-10/15

Ian Beh, Visiting Medical Student, Cambridge University College of Medicine, Cambridge UK Research Elective Mentor 6/15 – 8/14

Ahmed Noor, Visiting Medical Student, Windsor University School of Medicine, Research Elective Mentor, 1/15-3/15.

Valentina Ferri, Ph.D. physics trainee, University of Bologna, Santa Maria Nuova Hospital in Reggio Emilia, Italy 9/15-10/15. Present position: Medical Physicist Stanford University

Ahmed Noor, MD Volunteer, 9/15-12/15

GS 8/27/2021 37 sgourosCV_2021_08-27

Ivan Guan Bioengineering undergrad, 2016

Aneesh Patankar Bioengineering undergrad, 2016

Nader Moshiri, Ph.D. candidate, Florida Atlantic University, 2016-2017

Akhila Rao, Bioengineering Hopkins undergrad 2017-2018

Zachary Austin, (URM) Hopkins CUPID Summer 2016

Alireza Karimian, Ph.D. visiting professor, Isfahan University, Isfahan, Iran. 1/17-8/17

Cyrus Washington (URM) CUPID Summer 2017

Abigail Shtekler Summer intern 2018

Kaitlyn Louie Summer student 2018

Indiraman Sunner Summer intern 2018

Alexander Tejeda (URM) CUPID Summer 2018

Ryan Scott (URM) MERIT Scholar 2018

Maximo McCarty Summer student 2018

Jasmine Byard (URM) AAPM summer student 2018

Nathan Ji Bioengineering/Applied Math Hopkins Undergrad 2019

Ryan Lu Computer Science/Bioengineering Hopkins Undergrad 2019

Roberto Fedrigo AAPM summer undergrad 2019

Jessica Gilchrist AAPM summer undergrad 2019

Ioanna Liatsou, postdoc10/2019-

Jing Yu, postdoc 3/2019 –9/2020 Present position: J&J pharmaceutical in PA

Remco Bastiaannet, postdoc 04/2020-

Joseph Piccolo AAPM summer undergrad 2020

Amber Robinson, Morgan State University-Hopkins Summer Program 2021

Christopher Loerke, (URM) Hopkins CUPID Summer 2021

GS 8/27/2021 38 sgourosCV_2021_08-27

Nicole Saad, high school summer student 2021

Corrie Burroughs, AAPM DREAM summer undergrad 2021

Christina Taylor, Johns Hopkins Summer Jobs Program Summer 2021

Ph.D. Thesis committees

Kristina Norrgren, “Radiolabeled Monocolonal Antibodies, Development of a New Method to Remove Circulating Activity – Diagnostic Applications and Implications for Therapy,” Guest opponent, oral defense, Lund, Sweden, 1993.

Eli Furhang, “A Monte Carlo-Based Dosimetry Method For Patient-Specific Internal Emitter Therapy” Columbia University Grad Student, Applied Physics Co-Ph.D. Advisor (w/ Chen Chui, Ph.D., MSKCC); ‘95-‘97

Peter S. Kim, “Characterization of the Biophysical, Molecular, and Immunological Consequences of Antibody-Tumor Interaction on the Development of Potent Antitumor Immunity,” Johns Hopkins University, School of Medicine, Department of Pharmacology and Molecular Sciences Thesis Advisory Committee Member 2005-2007

Bin He, Medical Imaging Physics Division, Department of Radiology Examining Committee Member, 2005-2006, Ph.D

Chris Watchman, “Alpha Particle Dosimetry: 3D Image based Models of Normal Bone for use in Radionuclide Therapy,” University of Florida, Department of Nuclear and Radiological Engineering. Thesis Advisory Committee Member 2003-2005

Andrew L. DuFresne, Johns Hopkins University, School of Medicine, Biochemistry, Cellular, and Molecular Biology Program Thesis Advisory Committee Member 2008-

Thomas Bäck, University of Gothenburg, Invited Opponent, Ph.D. Thesis Defense, May 2011

Michael Wayson, “Computational internal dosimetry methods as applied to the University of Florida series of hybrid phantoms” University of Florida, J. Crayton Pruitt Family Department of Biomedical Engineering. Examining Committee Member 2011-2012.

Lishui Cheng, “Development and characterization of convergent and fast penalized SPECT image reconstruction methods for targeted radionuclide therapy dosimetry” Thesis Advisory Committee Member 2011-2013

Xing Rong, “Development and evaluation of quantitative Y-90 bremsstrahlung SPECT methods” Thesis Advisory Committee Member 2011-2013

Nate Crookson, Chair, advancement to candidacy exam Electrical and computer science engineering, Hopkins, October 2016

GS 8/27/2021 39 sgourosCV_2021_08-27

Gary Li, Ph.D. oral exam committee Electrical and computer science engineering, Hopkins, October 2019

Dominick Salerno, Sofou PhD student (thesis Committee)

Editorial Activities

Reviewer: Cancer Biotherapy and Radiopharmaceuticals, Cancer Research, Clinical Cancer Research, International Journal of Cancer, Journal of Nuclear Medicine, Medical Physics, Physics in Medicine and Biology, International Journal of Radiation Biology, PLoS

Guest Editor: Medical Physics, Journal of Nuclear Medicine

Editorial Board Member: Cancer Biotherapy and Radiopharmaceuticals

Scientific and Medical Societies

Society of Nuclear Medicine American Association of Physicists in Medicine American Association for Cancer Research American Association for the Advancement of Science

Committees/Review Panels

Steering Committee Member (1995-2000), American Association of Physicists in Medicine (AAPM), Task Group on Internal Emitter Dosimetry Chairman (1996), Dosimetry, Physics and Radiobiology Panel, Department of Energy, Alpha-Emitters for Medical Therapy Workshop Chairman (1997-2003), Sub-Committee on Non-Human Use, Committee on Radiation, Memorial Sloan-Kettering Cancer Center Study Section Member ('97, '98), Biomedical Research Technology Special Emphasis Panel National Center for Research Resources, National Institutes of Health NCI Program Project Study Section Site Visit, City of Hope National Medical Center (’99) Study Section member, Advanced Nuclear Medicine Initiative, Dept. of Energy ('00) Member (2000 - ), Vice Chairman (2006 - 2008), Chairman (2008 - 2019 ) Medical Internal Radiation Dose (MIRD) Committee, Society of Nuclear Medicine Oncological Sciences IRG Study Section Boundaries Team member (2001), NIH, Center for Scientific Review "develop recommendations for … study sections that will be responsible for reviewing grant applications in the oncological sciences"

GS 8/27/2021 40 sgourosCV_2021_08-27

Member, National Council on Radiation Protection and Measurements (NCRP), Scientific Committee 6-3, Uncertainties in Internal Radiation Dosimetry (2005-2010) Member, Board of Directors, Molecular Imaging, Center of Excellence, Society of Nuclear Medicine (2007) DOD Breast Cancer Research Program (2007, 2008) Member, Breast Cancer Review Training Panel Study Section Member (2008) NIH, National Institute of Allergy and Infectious Diseases, Special Emphasis Panel Mechanisms, Diagnosis, and Treatment of Radiation Injury from Nuclear Accident or Terrorist Attack Organizing Committee Member (2009) International Atomic Energy Association (IAEA), International Symposium on Standards, Applications and Quality Assurance in Medical Radiation Dosimetry, Vienna Austria Chair, Organizing Committee (2008-2009), International Symposium on Radionuclide Therapy and Radiopharmaceutical Dosimetry (ISRTRD), Toronto, Canada DOD Breast Cancer Research Program (2010) Member, Breast Cancer Review Training Panel Study Section Member (2010) NIH, NIBIB, Special Emphasis Panel Training/Career Opportunity Awards Member (2010-), Scientific Advisory Board, Orano Med, LLC Ad Hoc Reviewer (2011), Transplantation, Tolerance and Tumor Immunology (TTT) Study Section NIH Scientific Advisor (2012- ) Metrology for Molecular Radiotherapy (MetroMRT) grant from the European Metrology Research Programme, Joint Research Proposal Standing Study Section Member (2012-2017) NIH, Radiation Therapeutics and Biology (RTB) Council Member, (2013-) National Council on Radiological Protection and Measurements (NCRP) Member, Scientific Committee of the IAEA/WHO Network of Secondary Standards Dosimetry Laboratories, (2014-2018) Member, The International Commission on Radiation Units and Measurements (ICRU), Report Committee on “Bioeffect Modeling and Equieffective Dose Concepts in Radiation Therapy” (2014-) Chairman, Radiation Therapeutics and Biology (RTB) study section (2015-2017) Chairman, The International Commission on Radiation Units and Measurements (ICRU), Report Committee on “Treatment Planning for Radiopharmaceutical Therapy” (2016-) Member, IAEA Scientific Organizing Committee IDOS-2019

GS 8/27/2021 41 sgourosCV_2021_08-27

Chairman, Program Project Study Section (2018) NIH, NCI, Bethesda MD September 2018 Member, Ad hoc Working Group on Radiation Oncology (2019-), NIH, NCI, Clinical Trials and Translational Research Advisory Committee Co-Chair SNMMI Dosimetry Committee Task Force (2020-

Honors & Awards

New York State Regents Scholarship 1980 - 1984 Dean's Honor Roll, Columbia University 1980 - 1984 National Physics Honor Society 1983 National Engineering Honor Society 1983 Departmental nomination for 1984 George Vincent Wendell Award Columbia University, Applied Physics Dept. Cancer Research Institute/Jesselson Foundation Fellowship 1991 First Prize, American Association of Physicists in Medicine, 1993 Young Investigator Award - John Willins Awardee George Sgouros - senior author and supervisor. Louise and Allston Boyer Young Investigator Award, 1998 Memorial Sloan-Kettering Cancer Center, CaP CURE Award 2001 SNMMI Saul Hertz Award 2017 for outstanding achievements and contributions in radionuclide therapy Keynote Lecture, Australasian College of Physical Scientists and Engineers Meeting (EPSM) Adelaide, Australia 2018 Keynote Lecture, American College of Veterinary Radiologists (ACVR) Baltimore MD 2019

Invited Talks, Panels

“Radiation Effects on Brain Glucose Metabolism: Potential for Early Prediction of Damage using PET and MRS” Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, 1989.

“Conformal Treatment Planning for Radioimmunotherapy” Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, 1992

“Conformal Treatment Planning for Radioimmunotherapy” Center for Molecular Medicine and Immunology, Garden State Cancer Center, Newark, New Jersey, 1993

GS 8/27/2021 42 sgourosCV_2021_08-27

“Physicists Role in Clinical Radioimmunodiagnosis and Therapy” Scientific Symposium, Annual Meeting of the American Association of Physicists in Medicine, Washington, D.C., 1993

“The Role of Modeling and Dosimetry in Achieving Success with Radioimmunotherapy” Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, 1993

“Modeling and Dosimetry for Radiolabeled Antibody Therapy” Rheumatology Grand Rounds, Hospital for Special Surgery, New York, 1994

“Modeling and Dosimetry of Radiolabeled Antibodies: Identifying the Optimal Parameters for Radioimmunotherapy” Brookhaven National Laboratory, Upton, New York 1995

“Treatment Planning for Internal Emitter Therapy: Methods, Applications, and Clinical Implications” Invited Paper, 6th International Radiopharmaceutical Dosimetry Symposium, Gatlinburg TN 1996

“Alpha Particle Emitters in Cancer Therapy: Establishing the Rationale and Overcoming the Difficulties," "Internal Emitter Dosimetry: Are Patient-Specific Calculations Necessary?” “Mathematical Models of Tumour Growth: Translating Absorbed Dose to Tumour Control Probability” Keynote Speaker, Engineering & Physical Sciences in Medicine & Health Conference, Canberra, Australia, 1996

“Patient-Specific Dosimetry” Invited presentation, International Research Group in Immunoscintigraphy and Immunotherapy, Barcelona, Spain, May 1998.

“Patient-Specific Dosimetry” Invited presentation, International Research Group in Immunoscintigraphy and Immunotherapy, Göttingen, Germany, May 1999.

“Spheriod Studies with Alpha-Emitter Labeled Antibodies” Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, 2000.

“Preliminary Experience with Three-Dimensional Dose Assessment and Treatment Planning” Continuing Education session, Annual Meeting, Society of Nuclear Medicine, St. Louis MO, 2000.

“Dosimetry for Antibody and Peptide based Radionuclide Therapy” Nuklearmedizinische Klinik und Poliklinik, Technische Universität Munchen, 2000.

“Patient Dosimetry for 213Bi-HuM195” Medical Internal Radionuclide Dose (MIRD) Committee meeting, Delray Beach, FL, 2000

“Clinical Dosimetry Studies”

GS 8/27/2021 43 sgourosCV_2021_08-27

Invited Presentation, 7th International Radiopharmaceutical Dosimetry Symposium, Nashville TN 2002

“Radionuclide Therapy and Dosimetry” Invited Presentation, European Association of Nuclear Medicine Annual Congress, Vienna, Austria 2002

“Alpha-Particle Emitter (225Ac)-labeled Herceptin Antibody Targeting of Breast Cancer: Efficacy Vs. HER-2/neu Expression” Invited Presentation, Era of Hope, DoD Breast Cancer Research Program Meeting Orlando, FL, 2002

“The Radiation Physics of Targeted Therapy” Educational Symposium, Society of Nuclear Medicine mid-winter meeting Anaheim, CA. 2004

“Predicting Response and Toxicity: The Role of Dosimetry” 2nd International Workshop on Nuclear Oncology Aventura, FL. 2004

“Innovations in Tumor Dosimetry – Implications for Radioisotope Therapy Treatment Planning” Categorical Seminar, Society of Nuclear Medicine Philadelphia, PA. 2004

Panel Discussion: “The Future of Radioimmunotherapy” Panel Member, 10th Conference on Cancer Therapy with Antibodies and Immunoconjugates Princeton NJ, 2004

“Trends in Dosimetry for Therapy” Translational Applications of Molecular Imaging and Radionuclide Therapy Toronto, Canada. 2005

“Pre-Clincial Model for Targeted Alpha-Emitter Therapy of Early Breast Cancer Metastases” Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center New York NY 2005

“Radioimmunotherapy and Lack of Dosimetry and Standards” 14th Annual Meeting Council on Ionizing Radiation and Measurement Standards Gaithersburg MD 2005

“Skeletal Dosimetry at Johns Hopkins University” Mini-Symposium on Skeletal Dosimetry Advanced Laboratory for Radiation Dosimetry Studies, Dept. of Nuclear and Radiological Engineering, University of Florida Gainesville FL 2005

“Dosimetry for Radionuclide Therapy” Fudan University Hospital Shanghai, China 2005

GS 8/27/2021 44 sgourosCV_2021_08-27

“New Dosimetric Methods: Voxel-based Dosimetry” European Association of Nuclear Medicine, Annual Meeting; 2nd International Symposium on Radionuclide Therapy and Radiopharmaceutical Dosimetry Athens, Greece 2006

“Radiation Biology and Individual Patient Dosimetry in Therapeutic Nuclear Oncology” World Congress of Nuclear Medicine and Biology Seoul, S. Korea 2006

“Modeling and Dosimetry for Targeted Radionuclide Therapy” MD Anderson Cancer Center Department of Experimental Diagnostic Imaging Houston TX 2007

“Radioimmunotherapy and Targeted Alpha-Particle Therapy” The Baltimore-Washington Chapter of the Health Physics Society and The Mid-Atlantic Chapter of the American Association of Physicists in Medicine Columbia, MD 2007

“Regional (AFRA) training course on medical internal dosimetry relevant to nuclear medicine” International Atomic Energy Agency Technical Cooperation Project RAF/6/032: Promoting Regional and National Quality Assurance Programmes for Medical Physics in Nuclear Medicine (AFRA II-7) Tunis, Tunisia, N. Africa Nov. 2007

“Update on Dosimetry-Based Techniques in Thyroid Cancer” CME course: Nuclear Oncology from Genotype to Targeted Radionuclide Therapy Johns Hopkins University, Baltimore MD March 2008

“Targeted Therapy with Alpha-Particle Emitters - Dosimetry” CME course: Nuclear Oncology from Genotype to Targeted Radionuclide Therapy Johns Hopkins University, Baltimore MD March 2008

“Antibody-Targeted Liposomes in Cancer Therapy and Imaging” Pfizer, Inc. Cambridge MA April 2008

“The Emerging Role of Radiotherapeutics in Oncology” Grand Rounds, FDA, Silver Spring MD April 2008

“Radionuclide Therapy and Dosimetry in Nuclear Medicine” Scientific Symposium, Annual Meeting of the American Association of Physicists in Medicine Houston, TX, July 2008

“Dosimetry for Radionuclide Therapy” Oncology Research Institute (ORI)/NUMI & Cancer Research Centre of Excellence National University of Singapore Singapore Novemeber 2008

GS 8/27/2021 45 sgourosCV_2021_08-27

“Radionuclide Dosimetry and Targeted Alpha-Emitter Therapy” Grand Rounds, Department of Radiation Oncology and Molecular Radiotherapeutics, Johns Hopkins University, School of Medicine Baltimore MD, March 2009.

“Immunoliposomes for Targeted Radionuclide Therapy” Scientific Symposium, Annual Meeting of the American Association of Physicists in Medicine Anaheim, CA, July 2009

“Targeted Alpha-Particle Emitter Therapy of Metastatic Breast Cancer” Translational Research Conference, Johns Hopkins University, School of Medicine Baltimore MD, October 2009

“Targeted alpha-emitter therapy and Patient-Specific 3D-Radiobiological Dosimetry (3D-RD)" Radiation Epidemiology Branch, NIH NCI Bethesda MD, October 2009

“3D-RD Patient-Specific Dosimetry for Thyroid Cancer” Washington Hospital Center Washington DC, December 2009

“Introduction: Internal Dosimetry for Radionuclides” Joint International Center for Theoretical Physics-International Atomic Energy Association Advanced School on Internal Dosimetry Trieste, Italy, April 2010

“3D-RD Imaging-Based Dosimetry” Joint International Center for Theoretical Physics-International Atomic Energy Association Advanced School on Internal Dosimetry Trieste, Italy, April 2010

“Bexxar Dosimetry” Joint International Center for Theoretical Physics-International Atomic Energy Association Advanced School on Internal Dosimetry Trieste, Italy, April 2010

“2009 MIRD Committee Recommendations for Unifying MIRD and ICRP Formulas, Quantities, and Units” Joint International Center for Theoretical Physics-International Atomic Energy Association Advanced School on Internal Dosimetry Trieste, Italy, April 2010

“PET Quantification” Joint International Center for Theoretical Physics-International Atomic Energy Association Advanced School on Internal Dosimetry Trieste, Italy, April 2010

GS 8/27/2021 46 sgourosCV_2021_08-27

“Dosimetry for Targeted Radionuclide Therapy” Workshop: Functional Imaging for Radiotherapy Vancouver, Canada, April 2010

“Modeling and Dosimetry for Targeted Radionuclide Therapy” SCK-CEN, Belgian Nuclear Research Centre Mol, Belgium, July 2010

“Modeling and Dosimetry for Targeted Radionuclide Therapy” Munich Technical University Munich, Germany, July 2010

“Patient-Specific Dosimetry and Targeted alpha-emitter therapy” Brigham and Women’s Hospital, Dana Farber Cancer Institute Boston MA October, 2010

Keynote lecture, “Alpha-Particle Emitter Therapy: Radiobiology and Dosimetry” Targeted Alpha-Radionuclides to Combat Cancer (TARCC) Consortium Congress Ljubljana, Slovenia, November 2010

Keynote lecture, “Dosimetry in Radiopharmaceutical Therapy” Swiss Society of Radiobiology and Medical Physics, Annual Meeting Bern, Switzerland, November 2010

“Dosimetry for Radiopharmaceutical Therapy: Past, Present and Future” CME Course, Society of Nuclear Medicine, Mid-Winter Meeting Palm Springs CA, January 2011

“Dosimetry for Radiopharmaceutical Therapy” Division of Medical Imaging Physics, Dept. of Radiology Johns Hopkins University, SOM Baltimore MD, March 2011

“Targeted Alpha-Particle Emitter Therapy of Breast Cancer: Sidestepping some of the Biological Obstacles to Treatment Efficacy” Breast Cancer Novel Therapeutics/Correlative Sciences Working Group, Med Onc Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital Baltimore MD May 2011

“Alpha-Particle Emitter Therapy: A New and Promising Cancer Therapy” Invited Opponent, Ph.D. defense of Thomas Bäck Gothenburg University Gothenburg, Sweden May 2011

“Quantities and Units related to Deterministic Effects” CME Course, Society of Nuclear Medicine, Annual Meeting San Antonio, Texas, June 2011

GS 8/27/2021 47 sgourosCV_2021_08-27

“Alpha-Particle Emitter Dosimetry: The Fallible Mean” 7th Symposium on Targeted Alpha Therapy Berlin, Germany July 2011

IAEA Consultant’s meeting on internal dosimetry Vienna, Austria September 2011

“Dosimetry in Radiopharmaceutical Diagnosis and Therapy” FDA Visiting Professor Lecture Silver Spring MD, December 2011

“Evolution in Modeling and Dosimetry of Radioimmunotherapy” World Radioimmunoconjugate Summit Washington DC, January 2012

“I-124 PET/CT in Patient-Specific Thyroid Dosimetry for Treatment Planning” 21st Interdisciplinary Medical Symposium, 251st Air Force General Hospital Athens, Greece, February 2012

IAEA Consultant’s meeting on IAEA contributions to Nuclear Medicine Physics Vienna, Austria June 2012

“Individualized Pediatric Dosing Guidance” Royal Marsden Hospital and Institute of Cancer Research Sutton, UK June 2012

Scientific Advisor, European Metrology Centres grant member’s meeting on Metrology for Molecular Radiotherapy London, UK June 2012

“How to Improve Dosimetry for Radiopharmaceutical Therapy” “Alpha-Emitters in Nuclear Medicine Therapy: Overview” Annual Congress of the European Association of Nuclear Medicine Milan, Italy October 2012

Scientific Advisor, European Metrology Centres grant member’s meeting on Metrology for Molecular Radiotherapy Delft, Netherlands December 2012

“Radiopharmaceutical Dosimetry Workshop” “Treatment Planning and Dosimetry for Alpha-Emitters” World Radioimmunoconjugate Summit Washington DC, February 2013

“Treatment Planning for Alpha-Emitter Therapy” 2nd World Congress on Ga-68, Molecula Imaging, Targeted Radionuclide Therapy and Dosimetry Chandigarh, India, March 2013

GS 8/27/2021 48 sgourosCV_2021_08-27

“Targeted Alpha-Emitter Therapy of Breast Cancer: Pathways to a Phase I trial” Breast Cancer Novel Therapeutics/Correlative Sciences Working Group, Med Onc Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital Baltimore MD March 2013

“Physics of Radionuclide Therapy” NCI/SNMMI joint workshop on Targeted Radionuclide Therapy National Institutes of Health Campus Bethesda MD March 2013

“Matching the Method with the End-Point: Dosimetry for Radiopharmaceutical Therapy” Cancéropôle International Young Investigators Workshop: Radiobiology Applied to Oncology Domaine de Ramonjuan – Vallée de Lesponne France April 2013

“Radiobiology and Mechanism of Action of Radium-223” prIME Oncology Symposium, SNMMI Annual Meeting Vancouver BC, Canada June 2013

“Dosimetry and Radiobiology of alpha-Particle Emitters” IAEA Technical Meeting on: Alpha Emitting Radionuclides and Radiopharmaceuticals for Therapy Vienna, Austria June 2013

Scientific Advisor European Metrology Centres grant member’s meeting on Metrology for Molecular Radiotherapy Rome, Italy July 2013

“Treatment Planning for Alpha-Emitter Radiopharmaceutical Therapy” Workshop on Innovative Personalized Radioimmunotherapy Nantes, France July 2013

IAEA Expert Mission, “National Meeting and Workshop on Qualification and Diffusion of Quantitative Emission Tomography (PET/CT and SPECT/CT)” Sao Paulo, Brazil Dec, 2013

IAEA 16th Biennial Meeting of the SSDL Scientific Committee for the Evaluation of and Recommendations on the Dosimetry Programme and the IAEA/WHO SSDL Network, Vienna, Austria March 2014

European Society for Therapeutic Radiology and Oncology (ESTRO), 33rd Annual Meeting, “Dosimetry: The worlds of radionuclides and external beams - incongruent and incompatible?” Vienna, Austria April 2014

American Society of Clinical Oncology (ASCO), 50th Annual Meeting Chair, Radiopharmaceuticals: Spanning Hematologic Malignancies to Solid Tumors Speaker: Preclinical models of radioimmunotherapy/antibody conjugates: Translation to the

GS 8/27/2021 49 sgourosCV_2021_08-27

clinic Chicago, IL May 2014

Scientific Advisor European Metrology Centres grant member’s meeting on Metrology for Molecular Radiotherapy Paris, France May 2014

Radiology Translational Research Seminars, Rapid Fire Presentation – Research in Nuclear Medicine – Radiopharmaceutical Therapy and Dosimetry Lab Johns Hopkins University, SOM, Dept of Radiology, May 2014

Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting CME: “Radiobiology and Dosimetry of Alpha-Particle Emitter Therapy” St. Louis MO June 2014

Biennial Prostate Cancer UK Forum, “Radiopharmaceutical Therapy” Baltimore MD, June 2014

Winthrop Rockefeller Cancer Institute Forum “Radioactive Pharmaceuticals that Target Cancer Cells-A Different Type of Targeted Biologic Therapy” Little Rock AK, September 2014

ICMIC lecture, “Prospects for Combination Radiopharmaceutical Therapy” Dept of Radiology, Johns Hopkins University, School of Medicine Baltimore MD, September 2014

Johns Hopkins University, School of Medicine Translational Research Conference “Radioactive Pharmaceuticals that Target Cancer Cells-A Different Type of Targeted Biologic Therapy” Baltimore MD, October 2014

Scientific Advisor European Metrology Centres grant member’s meeting on Metrology for Molecular Radiotherapy Prague, Czech Republic December 2014

Johns Hopkins University, School of Medicine Sarcoma Work in Progress Conference “Radioapharmaceutical therapy of Osteosarcoma” Baltimore MD, January 2015

Scientific Advisor European Metrology Centres grant member’s meeting on Metrology for Molecular Radiotherapy Thessaloniki, Greece, May 2015

Theagenion Hospital Cancer Center Patient-Specific 3D Dosimetry in Molecular Radiotherapy Thessaloniki Greece, May 2015

GS 8/27/2021 50 sgourosCV_2021_08-27

9th Symposium on Targeted Alpha Therapy Moderator, Dosimetry and Instrumentation Session Warsaw, Poland, May 2015

Genentech/Roche Scientific Advisory Board meeting on alpha-particle therapy/dosimetry “Radiopharmaceutical Therapy and Treatment Planning in the Era of Precision Medicine” Basel, Switzerland, July 2015

Bayer HealthCare, Alpha Particle Dosimetry Seminar “Dosimetry and Radiobiology for Alpha-Emitter Therapy: Transitioning from Cells and Mice to Humans” Berlin, Germany September 2015

Chairman and speaker IAEA Consultants Meeting “Dosimetry and Radiobiology for Alpha-Particle Emitter Therapy” Vienna, Austria, November 2015

University of Saskatoon, Symposium on Radiotherapeutics “Radiopharmaceutical therapy with beta and alpha-particle emitters in the Era of Precision Medicine” Saskatoon, Saskatchewan, Canada October 2015

Columbia University, Visiting Professor Lecture “Treatment Planning for Radiopharmaceutical Therapy” (invited lecture) “Dosimetry for Radiopharmaceutical Therapy vs Diagnosis” (fellows lecture) New York NY, January 2016

Washington University in St Louis, School of Medicine, Visiting Professor Lecture “Treatment Planning for Radiopharmaceutical Therapy” St Louis MO, January 2016

Florida Atlantic University, Visiting Professor Lecture “Dosimetry and Radiobiology for Alpha-Particle Emitter Therapy” Boca Raton FL, February 2016

Johns Hopkins University, SOM, Radiation Oncology Retreat, keynote speaker “Radiopharmaceutical Therapy in the era of Precision Medicine” Baltimore MD, February 2016

IAEA 17th Biennial Meeting of the Secondary Standards Dosimetry Lab (SSDL) Scientific Committee for the Evaluation of and Recommendations on the Dosimetry Programme and the IAEA/WHO SSDL Network, Vienna, Austria March 2016

Memorial Sloan-Kettering Cancer Center Keynote Lecture, “Modern Radiation Dosimetry for Targeted Radiotherapy,” Imaging and Radiation Sciences (IMRAS) Research Symposium New York NY May 2016

GS 8/27/2021 51 sgourosCV_2021_08-27

Johns Hopkins University, School of Medicine Fellows Research Conference “Radiopharmaceutical Therapy in the Era of Precision Medicine” Baltimore MD, September 2016

FDA, Invited presentation on internal dosimetry “Dosimetry for Radiopharmaceutical Therapy” Silver Spring MD, October 2016

Radiation Research Society, Continuing Medical Education Session “Radiopharmaceutical Therapy in the Era of Precision Medicine” Big Island HA, October 2016

Johns Hopkins CME “Precision Medicine in the Context of Radiopharmaceutical Therapy” Baltimore MD March 2017

Johns Hopkins Medical Oncology, Sarcoma Workshop “Radioapharmaceutical therapy of Osteosarcoma” Baltimore MD March 2017

Johns Hopkins – Bayer Pharmaceuticals Immunoncology Workshop (organizer) “Radiopharmaceutical Therapy with α-emitters” Baltimore MD April 2017

Johns Hopkins – Siemens Workshop “Patient-Specific 3D Dosimetry in Radiopharmaceutical Therapy” Baltimore MD April 2017

10th International Symposium on Targeted Alpha Therapy Session Chair, Dosimetry and Instrumentation Kanazawa, Japan June 2017

Saul Hertz Award, Society of Nuclear Medicine and Molecular Imaging (SNMMI) “Radiopharmaceutical Therapy: Current Status and Future Prospects” Denver CO June 2017

Annual meeting, Categorical Seminar, Society of Nuclear Medicine and Molecular Imaging (SNMMI) “Biokinetic Models for Pediatric Dosimetry” Denver CO June 2017

Annual meeting, American Association of Physicists in Medicine (AAPM) “The first precision medicine approach to treating cancer - Dosimetry for radioiodine therapy of thyroid cancer” Denver Co July 2017

Johns Hopkins, Radiology “Grant Preparation/Guiance Tutorial” Baltimore MD August 2017

GS 8/27/2021 52 sgourosCV_2021_08-27

European Association of Nuclear Medicine (EANM) “Treatment Planning for Alpha-Emitter Radiopharmaceutical Therapy” Vienna, Austria, October 2017

University of Pennsylvania, Radiobiology and Imaging Program Retreat, Keynote Speaker “Dosimetry and Radiobiology for Radiopharmaceutical Therapy” Philadelphia PA December 2017

Annual Meeting, National Council on Radiation Protection and Measurements (NCRP) “Radiopharmaceutical Therapy” Bethesda MD March 2018

NCI Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy “Available SRT Dosimetry Methods/Approaches” “Alpha-Emitter-Specific Dosimetry Issues” “Bismuth-213” Rockville MD, April 2018

Johns Hopkins, 4th Quarter Course, New Approaches to Cancer Prevention and Therapy “Radiopharmaceutical Therapy with Alpha-Particle Emitters” Baltimore MD, April 2018

American Association for Cancer Research (AACR) and the AACR Radiation Science and Medicine Working Group (RSM), AACR Radiation Science and Medicine Think Tank: Illuminating Technological Advances and Challenges in Precision Radiotherapies “Radiopharmaceutical Therapy” Philadelphia PA April 2018

Johns Hopkins, Sydney Kimmel Cancer Center, Post-Doctoral Fellow Association “Grant Preparation/Guiance Tutorial” Baltimore MD June 2018

Society of Nuclear Medicine and Molecular Imaging, Therapy Center of Excellence “Dosimetry: the Well-Credentialed Biomarker” Philadelphia PA June 2018

International Commission on Radiological Units (ICRU), Report Committee, Treatment Planning in Radiopharmaceutical Therapy Meeting organizer, chair of sessions Reykjavik, Iceland August 2018

MRT Dosimetry “Dosimetry in Clinical Trial Design: Making the case” Prague, Czech Republic Septemer 2018

Children’s Oncology Group Annual Meeting (COG) “Rationally Combining Radiopharmaceutical Therapy and Radiotherapy in Clinical Trials” Dallas TX, October 2018

GS 8/27/2021 53 sgourosCV_2021_08-27

European Association of Nuclear Medicine (EANM) “Setting the Standard for Treatment Planning in Radiopharmaceutical Therapy: ICRU Task Group 31” Dusseldorf, Germany, October 2018

Australasian College of Physical Scientists and Engineers Meeting (EPSM) “Radiopharmaceutical Therapy with alpha-particle-emitters” “Radiopharmaceutical therapy: The role of dosimetry in treatment optimization” “Radionuclide Dosimetry & Radiobiology” Adelaide, Australia, October 2018

NCI invited presentation “The Case for Dosimetry in Clinical Trial Evaluation of Radiopharmaceuticals” Bethesda MD December 2018

11th International Symposium on Targeted-Alpha-Therapy keynote speaker “The Case for Dosimetry in Alpha-Emitter Radiopharmaceutical Therapy” Ottawa, Ontario Canada April 2019

Society of Nuclear Medicine and Molecular Imaging Categorical Seminar - Theranostics: Regulatory Considerations for Product Development “Non-Clinical Dosimetry and PK, Absorbed Doses and Alpha Emitters” Anaheim CA June 2019

NRG Oncology Targeted Radiopharmaceutical Therapy (TRT) Workshop “Radiopharmaceutical Imaging and Dosimetry” Philadelphia July 2019

Workgroup member NCI Clinical Trials and Translational Research Advisory Committee (CTAC) Translational Research Strategy Subcommittee (TRSS) Ad hoc Working Group on Radiation Oncology (Rad Onc) Meeting Rockville MD August 2019

American College of Veterinary Radiologists (ACVR), Keynote presentation: “Delivering Radiation Packages to Cancer’s Doorstep” Baltimore, MD October 2019

International Commission on Radiological Units (ICRU), Report Committee, Treatment Planning in Radiopharmaceutical Therapy Meeting organizer, chair of sessions Barcelona, Spain October 2019

ICMIC presentation Hopkins, Radiology Why is radiopharmaceutical therapy the best cancer therapy for metastatic cancer; how can it be made better? Johns Hopkins University Baltimore MD February 2020

GS 8/27/2021 54 sgourosCV_2021_08-27

Events cancelled or delayed due to COVID-19

20_03 Baltimore Hopkins CME talk 20_03 Big Sky Montana Rad Res REMOTE 20_03 Leesburg SNMMI therapy COE strategy 20_04 Rad Onc retreat 20_05 Hopkins Lunch and Learn RPD 20_06 Munich Hanson RPT 20_06 SNMMI New Orleans 20_07 AAPM COMP Vancouver talk 20_07 Vancouver AAPM_ICRU 20_08 Bethesda NCI Instrumentation 20_08 NIBIB Workshop on Imaging Technology 20_09 ORNL Targeted Therapies 20_10 Brazilian Nuclear Bioscience (SBBN) Congress Foz de Iguazu

GS 8/27/2021 55 sgourosCV_2021_08-27